[STUDY_ID_REMOVED]
Phase II Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High 
Grade Glioma
04/22/2021
Virginia Commonwealth University Massey Cancer Center  
Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent 
High -Grade Glioma  
MCC  Protocol #:  MCC -14816 ( CTC-11-011) 
Principal Investigator:  
Mark Malkin, MD  
Version #:  12 Version Date:  04/22/2021 

MCC Protocol #:  MCC -14816  ii Version #: 1 2 
Version Date: 04/22/2021  SCHEMA  
Recurrent or progressive high -grade 
glioma; unselected patients  
•Sorafenib 400 mg orally
twice a day;
•Valproic acid (to levels ≥
LLN) orally twice a day;
•Sildenafil 50 mg orally
twice a day.
Titrate valproic acid to level 
≥ LLN for the laboratory  
Hold after enrollment of 16 
patients for interim analysis 
to determine the number of 
patients with 6 -month 
progression -free survival 
(PFS).  
If there are 4 or more 
patients with 6 -month PFS: 
continue to enroll unselected 
patients and complete 
enrollment onto the study.  
If there are 3 or fewer 
patients with 6 -month PFS: 
close accrual to unselected 
patients, cont inue study and 
enroll only patients with 
PDGFRα -positive tumors. 
Accrue to a total of 16 
evaluable patients (inclusive 
of patients with PDGFRα -
positive tumors in the first 
interim analysis) for second 
interim analysis.  
Hold after enrollment of 16 
PDGFR α-positive patients for 
interim analysis to determine the 
number of patients with 6 -month 
PFS.  
If there are 4 or more 
patients with 6 -month PFS: 
continue to enroll PDGFR α-
positive patients and 
complete enrollment onto 
the study.   
If there are 3 or fewer 
patients wi th 6-month PFS: 
close study due to failure to 
meet prespecified efficacy 
criteria in both unselected 
and selected cohort.  
MCC Protocol #:  MCC -14816   iii Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 

MCC Protocol #:  MCC -14816  iv Version #: 1 2 
Version Date: 04/22/2021 

MCC Protocol #:  MCC -14816  v Version #: 1 2 
Version Date: 04/22/2021 

MCC Protocol #:  MCC -14816   vi Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
.  

MCC Protocol #:  MCC -14816   vii Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
  
 
 
   
 
  
  
 
 
  
  
 
    
 
    
 
 
    
 
    
 
    
  
  
 
 
  
 
 
 

MCC Protocol #:  MCC -14816   viii Version #: 1 2 
  Version Date: 04/22/2021 TABLE OF CONTENTS  
 SCHEMA  ................................ ................................ ................................ ................................ ..... II 
 ................................ ................................ ................................ ...................  III 
LIST OF ABBREVIATION S ................................ ................................ ................................ .........  1 
1 BACKGROUND  ................................ ................................ ................................ .............  2 
1.1 RECURRENT OR PROGRESSIVE HIGH-GRADE GLIOMA  ................................ .......................  2 
1.2 SORAFENIB  ................................ ................................ ................................ ......................  2 
1.3 VALPROIC ACID ................................ ................................ ................................ ................  2 
1.4 SILDENAFIL  ................................ ................................ ................................ ......................  3 
1.5 SORAFENIB + VALPROIC ACID PRECLINICAL DATA ................................ .............................  4 
1.6 RATIONA LE ................................ ................................ ................................ ......................  6 
1.7 CLINICAL CONSIDERATIONS  ................................ ................................ ..............................  6 
1.8 CORRELATIVE STUDIES BACKGROUND  ................................ ................................ ..............  9 
1.9 RATIONALE FOR ADAPTIVE DESIGN  ................................ ................................ ...................  9 
2 OBJECTIVES  ................................ ................................ ................................ ................  9 
2.1 PRIMARY OBJECTIVE  ................................ ................................ ................................ ........  9 
2.2 SECONDARY OBJECTIVES  ................................ ................................ ................................ . 9 
2.3 EXPLORATORY OBJECTIVE  ................................ ................................ .............................  10 
3 STUDY DESIGN  ................................ ................................ ................................ ..........  10 
3.1 GENERAL DESCRIPTION  ................................ ................................ ................................ .. 10 
3.2 PRIMARY ENDPOINT  ................................ ................................ ................................ ....... 10 
3.3 SECONDARY ENDPOINTS  ................................ ................................ ................................  10 
3.4 EXPLORATORY ENDPOINT  ................................ ................................ ...............................  11 
4 PATIENT SELECTION  ................................ ................................ ................................  11 
4.1 INCLUSION CRITERIA  ................................ ................................ ................................ ...... 11 
4.2 EXCLUSION CRITERIA  ................................ ................................ ................................ ..... 12 
5 STUDY ENTRY AND WITH DRAWAL PROCEDURES  ................................ ...............  14 
5.1 REGISTRATION PROCEDURES  ................................ ................................ .........................  14 
5.2 STUDY DISCONTINUATION PROCEDURES  ................................ ................................ .........  14 
6 TREATMENT PLAN  ................................ ................................ ................................ .... 15 
6.1 BASELINE TESTS AND PROCEDURES  ................................ ................................ ...............  15 
6.2 SCHEDULE  ................................ ................................ ................................ .....................  15 
6.3 RADIOGRAPHIC EVALUATIONS  ................................ ................................ .........................  16 
6.4 TOXICITY ASSESSMENTS  ................................ ................................ ................................  16 
7 DOSE MODIFICATIONS  ................................ ................................ .............................  17 
7.1 SORAFENIB  ................................ ................................ ................................ ....................  17 
7.2 SILDENAFIL  ................................ ................................ ................................ ....................  24 
7.3 VALPROIC ACID ................................ ................................ ................................ ..............  24 
7.4 GENERAL CONCOMITANT MEDICATION AND SUPPORTIVE CARE GUIDELINES  ....................  26 
7.5 LABORATORY MONITORING AND CLINICAL EXAM ................................ ..............................  28 
7.6 DURATION OF THERAPY  ................................ ................................ ................................ .. 29 
7.7 MONITORING PATIENT  COMPLIANCE  ................................ ................................ ................  29 
7.8 DURATION OF FOLLOW UP ................................ ................................ ..............................  29 

MCC Protocol #:  MCC -14816   ix Version #: 1 2 
  Version Date: 04/22/2021 8 ADVERSE EVENTS: DEFI NITIONS AND REPORTIN G REQUIREMENTS  ..............  30 
8.1 DEFINITIONS ................................ ................................ ................................ ...................  30 
8.2 ADVERSE EVENT CHARACTERISTICS  ................................ ................................ ...............  31 
8.3 KNOWN AE LIST ................................ ................................ ................................ .............  32 
8.4 TIME PERIOD AND GRADE OF AE CAPTURE  ................................ ................................ ..... 32 
8.5 PROCEDURES FOR RECORDING AES, SAE S, QUALIFYING TOXICITIES , AND UPS ..............  32 
8.6 EXPEDITED REPORTING PROCEDURES FOR SAE S, UPS, AND QUALIFYING TOXICITIES  ..... 33 
9 PHARMACEUTICAL INFOR MATION  ................................ ................................ .........  33 
9.1 SORAFENIB  ................................ ................................ ................................ ....................  33 
9.2 VALPROIC ACID ................................ ................................ ................................ ..............  42 
9.3 SILDENAFIL  ................................ ................................ ................................ ....................  49 
9.4 DRUG PROCUREMENT AND ACCOUNTABILITY  ................................ ................................ .. 55 
10 MEASUREMENT OF EFFEC T ................................ ................................ ....................  55 
10.1  DEFINITIONS ................................ ................................ ................................ ...................  55 
10.2  RESPONSE CRITERIA  ................................ ................................ ................................ ...... 56 
10.3  CONSIDERATIONS FOR PATIENTS WITH MULTIFOCAL DISEASE  ................................ ..........  57 
10.4  TIMING OF IMAGING STUDIES  ................................ ................................ ..........................  57 
11 CORRELATIVE STUDIES  ................................ ................................ ...........................  58 
11.1  PDGFR Α EXPRESSION IN PRIMARY TUMOR SAMPLES  ................................ .....................  58 
11.2  TIMING OF SAMPLE COLLECTION AND ANALYSIS  ................................ ..............................  58 
11.3  COLLECTION OF SPECIMENS  ................................ ................................ ...........................  59 
11.4  HANDLING OF SPECIMENS  ................................ ................................ ..............................  60 
11.5  IMMUNOSTAINING OF SPECIMENS  ................................ ................................ ....................  60 
11.6  INTERPRETATION OF CORRELATIVE STUDY  ................................ ................................ ...... 60 
11.7  OTHER POTENTIAL PHARMACODYNAMIC MARKERS  ................................ .........................  60 
12 STUDY CALENDAR  ................................ ................................ ................................ .... 61 
13 STATISTICAL CONSIDER ATIONS  ................................ ................................ ............  64 
13.1  STUDY DESIGN  ................................ ................................ ................................ ...............  64 
13.2  SAMPLE SIZE/ACCRUAL RATES  ................................ ................................ .......................  64 
13.3  GENERAL STATISTICAL ANALYSIS  ................................ ................................ ....................  65 
13.4  ANALYSIS OF PRIMARY ENDPOINTS  ................................ ................................ .................  65 
13.5  ANALYSIS OF SECONDARY ENDPOINTS  ................................ ................................ ............  65 
13.6  SAFETY LEAD-IN, AND SAFETY STOPPING RULE ................................ ..............................  66 
13.7  EVALUABILITY FOR QUALIFYING TOXICITY , TOXIC ITY, RESPONSE  ................................ ..... 67 
14 DATA AND SAFETY MONI TORING PLAN (DSMP)  ................................ ..................  67 
14.1  STUDY TEAM ................................ ................................ ................................ ..................  67 
14.2  MONITORING AND AUDITING  ................................ ................................ ............................  68 
15 REGULATORY COMPLIANC E AND ETHICS  ................................ ............................  68 
15.1  ETHICAL STANDARD  ................................ ................................ ................................ ....... 68 
15.2  REGULATORY COMPLIANCE  ................................ ................................ ............................  68 
15.3  INFORMED CONSENT PROCESS  ................................ ................................ ......................  68 
15.4  PATIENT CONFIDENTIALITY  ................................ ................................ .............................  69 
16 DATA COLLECTION AND MANAGEMENT  ................................ ...............................  69 
MCC Protocol #:  MCC -14816   x Version #: 1 2 
  Version Date: 04/22/2021 16.1  CRF S AND DATA COLLECTION  ................................ ................................ ........................  69 
16.2  STUDY RECORD RETENTION  ................................ ................................ ...........................  69 
17 REFERENCES  ................................ ................................ ................................ .............  70 
APPENDIX 1. PERFORMA NCE STATUS CRITERIA  ................................ ...............................  73 
APPENDIX 2. COCKCROF T-GAULT EQUATION  ................................ ................................ .... 74 
APPENDIX 3. NYHA CLA SSIFICATION OF HEART  FAILURE  ................................ ...............  75 
MCC Protocol #:  MCC -14816   1 Version #: 1 2 
  Version Date: 04/22/2021 LIST OF ABBREVIATIONS  
ABC ATP-binding cassette  
AE Adverse event  
ALT Alanine aminotransferase  
ANC  Absolute neutrophil count  
AST Aspartate aminot ransferase  
BBB Blood brain barrier  
BP Blood pressure  
CBC  Complete blood count  
cGMP  Cyclic guanosine monophosphate  
CrCL  Creatinine clearance  
CRF Case report form 
CTCAE  Common Terminology Criteria for Adverse Events  
CTRL  Clinical and Translational Re search Laboratory  
DSM C Data and Safety Monitoring Committee  
ECOG  Eastern Cooperative Oncology Group   
EGFR  Epidermal growth factor receptor  
EIAED  Enzyme -inducing antiepileptic drug  
GBM  Glioblastoma  
HDAC  Histone deacetylase  
Hgb Hemoglobin  
IHC Immunoh istochemistry  
IRB Institutional Review Board  
LLN Lower limit of normal  
MCC  Massey Cancer Center  
NO Nitric oxide  
PDE5  Phosphodiesterase type 5  
PDGF R Platelet -derived growth factor receptor  
PFS Progression -free survival  
PI3 Phosphoinositide 3  
PRMC  Protocol Review and Monitoring Committee  
RANO  Response Assessment in Neuro -Oncology  
SAE Serious adverse event  
UP Unanticipated problem  
VCU  Virginia Commonwealth University  
VEGFR  Vascular endothelial growth factor receptor  
WBC  White blood cell count  
WNL Within normal limits  
 
MCC Protocol #:  MCC -14816   2 Version #: 1 2 
  Version Date: 04/22/2021 1 BACKGROUND  
1.1 Recurrent or Progressive High -Grade Glioma  
High-grade gliomas  are the most common malignant primary brain tumors in adults (2) and 
are associated with poor prognosis. Despite  optimal therapy, nearly all high -grade glioma s 
eventually recur. The median survival following recurrence is only 25 to 30 weeks for World 
Health Organization (WHO) grade IV gliomas and 39 to 47 weeks for WHO grade III 
gliomas (3, 4). GBMs  account for  approximately 60% to 70% of high -grade gliomas. 
Anaplastic astrocytomas  comprise 10% to 15%. Ana plastic oligodendrogliomas  and 
anaplastic oligoastrocytomas  combined represent 10% of high -grade glioma s. Less 
common tumors such as anaplasti c ependymoma s and anaplastic gangliogliomas make 
up the rest (5). 
Many target ed agents against these aberrant pathways or affecting glioma stem cell 
growth are unde r investigation in recurrent high -grade glioma . Bevacizumab (Avastin; 
Genentech, South San Francisco, CA), a monoclonal antibody against VEGF, has been 
studied extensive ly in this patient population. In a randomized, multicen ter, 
noncomparative phase 2 trial, the estimated 6 -month pr ogression -free survival  (PFS) rates 
for patients with recurrent GBM were 42.6% for bevacizumab alone and 50.3% for 
bevacizumab plus irinoteca n (6). Additional therapies are urgently needed . 
1.2 Sorafenib  
Sorafenib is a multi -targeted protein kinase inhibitor that was originally developed as an  
inhibitor o f RAF -1, a component of the ERK1/2 pathway . Sorafenib  was subsequently 
shown to inhibit multiple other kinases, including class III tyrosine kinase  receptors such as 
platelet -derived growth factor receptor s (PDGFR s), vascular endothelial  growth factor 
receptors (VEGFR s), c-Kit, and FLT3 . VCU investigator Dr Paul Dent and collaborators 
have shown in vitro that sorafenib , through its effects on the PDGFRs, can activate Src 
non-receptor tyrosine kinases, and that this effect plays a role in the activation of d eath 
receptors resulting in tumor cell death (7, 8). Lethality of sorafenib in cancer cells is 
enhanced by concomita nt histone deacetylase (HDAC) inhibitor exposure (9, 10). Cell 
death is through the extrinsic pathway  of apop tosis. 
In the USA, sorafenib is approved for the treatment of differentiated thyroid carcinoma 
refractory to radioactive iodine treatment , and renal cell and hepatocellular carcinomas.  
Ongoing studies in GBM have investigated sorafenib as a single agent  and in combination 
with mTOR inhibitors, epidermal growth factor receptor ( EGFR ) inhibitors, and 
bevacizumab.  To date,  there are no studies combining sorafenib with HDAC inhibitors  in 
high-grade glioma .  
1.3 Valproic Acid  
Valproic acid (sodium valproate, valproa te) is an anti -seizure medication in common 
medical use, and is referred to as a non-enzyme -inducing antiepileptic drug ( non-EIAED) . 
It is frequently  used in chemotherapy regimens due to the  fact that it does not modulate the 
cytochrome p450 system ; thus, valproic acid does not have many of the drug -drug 
interactions with standard chemotherapy agents that are common for other antiepileptic 
drugs. It has subsequently been shown that valproic acid also acts as a HDAC  inhibitor  
MCC Protocol #:  MCC -14816   3 Version #: 1 2 
  Version Date: 04/22/2021 (11). Valproic acid has been demonstrated at clinically relevant concentrations to inhibit 
class I (HDAC 1, 2, and 3, along with HDAC 8) and class II, subclass I HDACs (HDAC 4,5, 
and 7) (11).  
HDAC inhibitors  are a class of drugs that inhibit the enzymes that deacetylate histones  
(12). By regulating histone acetylation , chromatin condensation is changed and the levels 
of transcription may be altered. Many other proteins, including those  that are cytosolic , are 
also acetylated and it is pr obable that the actions of HDAC inhi bitors  involve both the 
regulation of gene expression (eg , FAS-ligand) , as well as regulating acetylation of other 
cytosolic proteins (eg , HSP90 ) (13). In previously published work in GI tumor cells by Dent 
and colleagues, HDAC inhib itors were shown to increase the levels of FAS -ligand , as well 
as its receptor CD95, both of which played a role in HDAC  inhibitor  toxicity  (7, 8). His 
group has more recently demonstrated that knockdown of CD95 protected CNS tumor 
cells from the combination of sorafenib and valproic acid (14).  
Valproic a cid in combination with temozol omide and radiotherapy is currently under 
investigation in the treatment of newly diagnosed GBM. There are over 10 studies, ongoing 
or recently completed, that have evaluated HDAC inhibitors in the treatment of CNS 
tumors, no ne of which are combined with sorafenib.  
1.4 Sildenafil  
Sildenafil is FDA approved for the treatment of both erectile dysfunction and pulmonary 
hypertension, and has been administered to men , women , and children on a chronic daily 
basis.  
Intracellular cycli c guanosine monophosphate (cGMP) levels reflect the balance of 
synthesis by guanylate cyclases and degradation by phosphodiesterases. Nitric oxide (NO) 
activates guanylate cyclase in diverse tissues including vasculature, and cGMP is the 
second messenger t hat induces smooth muscle relaxation and vasodilation. Sildenafil 
increases intracellular cGMP and induces vasodilation . This activity is generally attributed 
to selective inhibition of cGMP -specific phosphodiesterase type 5 (PDE5).  Sildenafil and 
PDE5 inh ibitors may also have other fu nctions that relate to anti cancer therapy, specifically 
relating to blood brain barrier (BBB) interactions and drug efflux mechanisms.  PDE5 
inhibitors have been shown to increase chemotherapy delivery to brain tumors in animal  
models, through increased tumor cGMP levels (15). ATP-binding cassette (ABC) proteins 
transport various molecules across extra - and intracellular  membranes. Silde nafil has also 
been shown to inhibit the ABCB1 and ABCG2  drug efflux pumps, and reverse  ABCB1 and 
ABCG2 mediated chem otherapeutic drug resistance (16). The ABCG2 tra nsporter has 
recently been shown to be the dominant transporter  that limits transport of sorafenib into 
the brain  (17). This is clinically relevant  as GBM is con sidered to be a diffuse disease, with 
many areas of tumor residing in areas of the brain with an intact BBB.  Inhibition of the 
ABCG2 transporter with sildenafil may increase sorafenib drug concentrations in the brain, 
improving sorafenib anti -tumor efficac y.  
To date, there are no CNS tumor studies utilizing drug efflux pump modulators , like 
sildenafil,  in conjunction with sorafenib.   
MCC Protocol #:  MCC -14816   4 Version #: 1 2 
  Version Date: 04/22/2021 1.5 Sorafenib + Valproic Acid Preclinical Data  
Dent and colleagues have tested the combination of sorafenib and HDAC  inhib itors in 
multiple GBM  isolates. These studies have included : GBM cells expressing  mutant active 
forms of the EGFR (GBM6, EGFR vIII; GBM12, mutant active full -length EGFR) , GBM 
cells lacking PTEN function (GBM14) , GBM cells expressing a mutant active 
phosphoinosi tide 3 ( PI3)-kinase and PDGFR α (GBM5) , or GBM cells with low levels of 
growth factor receptors (GBM15). There appear to be differences in drug combination 
sensitivity based on the molecular phenotype of the GBM cell line. S orafenib toxicity was 
enhanced by valproate in  the GBM6  EGFR m utant variant III  cells in a dose -dependent 
fashion (Figure 1). This mutation in EGFR leads to a truncated EGFR that is constitutively 
active, but does not bind ligand. GBM15 and GBM14 were both sensitive to the dr ug 
combination , similar to GBM6  (data not shown ).  
In the following figures, valproic acid (VAL) was the HDAC inhibitor used in combination 
with sorafenib (SOR).  
Percentage cell death
02040608024h 48hGBM6
*
*
*
*Figure 1VEH
SOR 3
VEH
SOR 6
VAL (1)
VEH
SOR 3
SOR 6VEH
SOR 3
SOR 6
VEH
SOR 3
SOR 6
VEH VAL (1)
 
Figure 1. GBM6 cells were treate d with vehicle or sodium valproate (1 mM). Thirty minutes later cells 
were treated with vehicle or sorafenib (3 µM; 6 µM). Cells were isolated 24 h and 48 h later. Viability was 
determined by trypan blue exclusion (n=3, +/ - SEM) * p<0.05 greater than corre sponding vehicle -control 
treated cells.  
GBM12  full-length EGFR mutant  cells appear to be more resistant to the drug combin ation 
than GBM6 truncated EGFR mutant cells ( Figure 2). 
MCC Protocol #:  MCC -14816   5 Version #: 1 2 
  Version Date: 04/22/2021  
The cells that were  clearly  most sensitive to the sorafenib and valpro ic acid  drug 
combination were GBM5 cells; cells that express one of the growth factor receptor targets 
of sorafenib, PDGFR α (Figure 3).  
 
Figure 3. GBM 5 cells were treated with vehicle or sodium valproate (1 mM). Thirty minutes later cells 
were treat ed with vehicle or sorafenib (1, 2, 3, or  6 µM). Cells were isolated 24 and 48  h later. Viability 
was determined by trypan blue exclusion (n = 3, +/ - SEM) * p < 0.05 gre ater than corresponding vehicle -
control treated cells.  
Collectively, this data suggests that the combination of sorafenib and valproic acid is worth 
investigating in GBM.  It appears from the preclinical data that different molecular 
phenotypes may have different sensitivities to the drug combination, and this will be 
investigated during the  study.   
Percentage cell death
020406080
SOR 1
SOR 2GBM5, 24h GBM5, 48h
****Figure 3 VEH
SOR 3
VEH
SOR 6
VAL (1) VEH VAL (1)SOR 1
SOR 2VEH
SOR 3
SOR 6SOR 1
SOR 2VEH
SOR 3
SOR 6SOR 1
SOR 2VEH
SOR 3
SOR 6Figure 2. GBM12 cells were 
treated with vehicle or sodium 
valproate (1 mM). Thirty minutes 
later cells were treated with 
vehicle or sorafenib (3 µM; 6 µM). 
Cells were isolated 48 h later. 
Viability was determined by trypan 
blue exclusion (n=3, +/ - SEM) * 
p<0.05 greater than 
correspondi ng vehicle control 
treated cells . 
MCC Protocol #:  MCC -14816   6 Version #: 1 2 
  Version Date: 04/22/2021 1.6 Rationale  
Promising single agent in vitro  activities and potentially complementary mechanisms of 
action suggest that the combination  of sorafenib, v alproic acid, and silden afil may have 
therapeutic potential for the treatment of high-grade glioma  in the clinic . The combination 
of sorafenib and valproic ac id is predicated on the basis that sorafenib activity is  enhanced 
by HDAC inhibition. The addi tion of sildenafil is based  on its ability to block ABCB1 and 
ABCG2 drug efflux pumps. As the ABCG2 transporter is the primary transporter involved in 
the efflux of sorafenib at the BBB, blocking its action is predicted to increase the 
concentration of sorafen ib in the brain.  
1.7 Clinical Considerations  
One dose level of sorafenib will be tested in this phas e 2 study. Sorafenib will be dosed at 
the FDA approved dose of 400 mg orally twice daily,  which is well established as the 
maximum tolerated dose for continuous  dosing. This dose of sorafenib has been tested in 
recurrent GBM in 5 separate phase 2 studies in combination with temozolomide (18, 19), 
temsirolimus  (20), erlotinib  (21), and bevacizumab  (22).  
In the study by Reardon et al (18), 12 patient s were taking CYP3A EIAEDs , 10 patient s 
were taking non -EIAED s, and 10 patient s were not taking any medication to prevent 
seizures  (valproic acid is a non -EIAED).  Overall, 4 patient s (13%)  required dose 
modification or discontinuation of sorafenib for grade 3 or 4 elevation of amylase/lipase, 
and 3 patient s (9% ) required dose modification or discontinuation of sorafenib for grade 3  
PPE. Only 2 of the 4 patient s with elevated amylase/lipase were symptomatic and in 1 of 
those 2 patient s, underlying galls tones were the likely etiology.  Of note, 5 out of 10 patient s 
on th e non -EIAED arm who underwent pharmacokinetic  sampling required sorafenib dose 
interruption or modifica tion during cycle 1 of therapy.  For patient s not on EIAEDs, day -28 
sorafenib AUC 0 -24 was signific antly higher compared to day 1.  This increase may  also 
have been mildly augmented by the discontinuation of dexamethasone (a mild CYP3A 
inducer) in 3 patient s. 
In the study by Zustovich et al (19), all patie nts (n=43) received oxcarbazepine, a hepatic 
CYP3A inducer (EIAED).  Grade 3 -4 toxicity was observed in 4 patient s (9%) with  PPE, 1 
patient  (2%) with diarrhea and 1 patient  (2%) with lipase elevation.  It is possible that if 
these patient s had been taking no n-EIAEDs the toxicity ascribed to sorafenib would have 
been higher.  
In the study by Lee et al (20), patient s receiving EIAE Ds were excluded.  In the phase 1 
componen t of the trial, 1/6 (1 7%) developed grade 3 diarrhea.  In the phase 2 component of 
the trial, 1/19 patient s (5%) developed grade 3 lipase elevation and 1/19 patient s (5%)  
experienced grade 3 diarrhea. The frequency of these toxicities is well below the thre shold 
of 35% that is proposed in the current study.  
Similarly, i n the study by Peereboom et al (21), patient s receiving EIAEDs were excluded.  
Grade 3 or 4 eve nts felt to be possibly, probably or definitely related to sorafenib or 
erlotinib ranged from 2% (elevated transaminases, PPE, diarrhea) to 7% (el evated lipase) 
to 9% (fatigue).  The elevation s of lipase were asymptomatic. The frequency of these 
toxicities is well below the threshold of 35% that is proposed in the current study. There 
were no unexpected toxicities.  
MCC Protocol #:  MCC -14816   7 Version #: 1 2 
  Version Date: 04/22/2021 In the study by Galanis et al (22), 3/19 patient s (16%) experienced grade 4 non -
hematologic toxicity and a 42% discontinuation rate.  Fatigue (which could be ascribed to 
sorafenib and/or bevacizumab) and hypertension (due to bevacizumab) were the 2 mos t 
commonly observed toxicities.  Decrease of the starting sorafenib dose from 200 mg twice 
daily to 200 mg daily resu lted in improved treatment tolerance.  
Unfortunately, in none of these 5 stu dies was notable efficacy seen.  Partial response rate s 
of 3-12%, 6-month PFS of 0-26% and overall survival  of 5.6-9.6 months were reported.  It is 
our hypothesis that the addition of  valproic a cid with its HDAC  activity, coupled with 
sildenafil with its drug efflux pump inhibitory activity, could synergistically increase the 
likelihood of GBM tumor cell kill without concomitant unacceptable sorafenib (or valproic 
acid) toxicity.  
Since  the accepted and expected rate of grade 3+ toxicities of sorafenib alone is 35%, the 
safety component in this trial will focus on identifying a measurable increase in t hat rate of 
overall toxicities.  The safety lead -in component of this study will serve t o screen for a n 
increase in early toxicities.  The safety stopping rule  will permit monitoring of both early and 
late toxicities, but practically speaking only becomes applicable if early toxici ties are 
deemed not excessive.  Note that grade 5 (fatal) toxici ty was not seen in any of the 5 
studies cited above.  
If toxicity is observed that could be ascribed to sorafenib, then the sorafenib dose will be 
modified according to Section 7. Likewise, if toxicity is observe d that could be ascribed to 
valproic acid, then the valproic acid dose will be modified according to Section 7, which  
simply follows G ood Clinical Practice  principles.  Total and free serum valproate levels can 
be obtained on a same -day basis from the clinical laboratory to help guide the investigator 
to the appropriate dose modification.  If toxicity is observed that could be ascribed to 
sildenafil, then the sildenafil dose will be modified according to Section 7. If sorafenib or 
valproic acid toxicity is observed, it is important to first modify the dose of sorafenib or 
valproic acid and maintain the sildenafil dose constant, since reducing the sildenafil dose 
may resul t in decreases of tumor tissue levels of both sorafenib and valproic acid, 
abrogating the therapeutic effect that this phase 2 trial is designed to achieve.  If dose 
modification of sorafenib or valproic acid does not reverse drug toxicity attributable to t hose 
agents, then subsequent sildenafil dose reductions may also be needed to accomplish that 
goal.  We believe this is a rational approach to optimize tumor cell kill while minimizing risk 
to study patient s. 
The FDA recommended initial dose of valproic aci d is 10 -15 mg/kg per day in divided 
doses; for the purposes of this study valproic acid will generally be dosed twice daily, to 
allow for ease of administration of all 3 agents at the same time. After initiation of therapy 
at 10 -15 mg/kg/day, escalation of  the dose over approximately 1 week to ≥ lower limit of 
normal ( LLN) will be performed. Prior research with valproic acid suggests that therapeutic 
concentrations of valproic acid  can inhibit histone deacetylation  (11, 23, 24). For patient s 
with a seizure disorder being treated with valproic acid, serum levels should be checked 1 
week af ter the initial dose; therapeutic concentrations are usually in the 50 -150 mcg/mL 
range.  For patients who develop neurologic deterioration, valproic acid levels will be 
checked to make sure that supratherapeutic drug concentrations are not the source of th e 
neurologic deterioration.  
It is generally accepted that patients with GBM and seizures should be treated with a non -
EIAED to minimize CYP3A -mediated drug interactions and, more specifically, to avoid 
MCC Protocol #:  MCC -14816   8 Version #: 1 2 
  Version Date: 04/22/2021 inadvertent lowering of cytotoxic drug concentrations in GBM tumor cells. Which non -
EIAED to choose is a matter of personal preference for the treating physician; there is no 
published practice parameter or “standard of care”. That said, there is a growing body of 
evidence that valproic acid is a logical firs t choice in this setting 1) because it is an 
effective AED and 2) be cause of its HDAC  activity. Weller et al (25) showed that GBM 
patient s receiving valproic aci d appeared to derive more survival benefit from 
temozolomide/radiotherapy than patient s receiving an EIAED or not receiving any AED.  
Guthrie et al (26) and Bark er et al (27) came to a similar conclusion. Felix et al (28) 
corroborated this observation in 94 children with a variety of primary CNS tumors.  
Furthermore, Kerkhof et al (29) demonstrated that valproic acid monotherapy conferred 
equivalent freedom from seizures (78%) as did levetiracetam (70%) in patient s with GBM.  
Therefore, we do not believe that patient s in this trial will be placed at any seizure control 
disadvan tage when treated with valproic acid and, indeed, may benefit from th e associated 
HDAC  activity directed against their tumor.  
Of note, there is a single case report describing the use of sorafenib plus valproic acid in 
an infant with a spinal GBM (30). Marked clinical and radiographic improvement was 
shown, and no sid e effects of the combination were  observed.   
Sildenafil will be dosed at 50 mg orally twice daily, at the time of sorafenib dosing. The 
purpose of twice daily dosing is to have maximal sildenafil concentrations at the time of 
sorafenib dosing, to maximize inhibition of ABC transport system and to try to maximize 
increases in sorafenib transport across t he BBB. This dosing schedule is less frequent 
than some dosing schedules used in pulmonary hypertension studies and heart failure 
studies. One study evaluating pulmonary hypertension in heart failure dosed sildenafil at 
50 mg , 3 times a day , for a period o f 12 months, and did not report significant toxicities 
(31).  
There are no major overlapping toxicities relating to valproic acid, sorafenib, or sildenafil 
that s uggest that the combination would be subject to higher rates of toxicity. There is a 
low incidence of diarrhea in patients treated with sorafenib that may be exacerbated with 
valproic acid; this will be monitored closely. There is an early stopping rule in  place should 
there be unexpected significant toxicities from the combination. It is expected from clinical 
experience that a fraction of patients will not tolerate full dose sorafenib in the chronic 
setting, and these patients may continue therapy at redu ced dose levels.  
One previously published study has evaluated sorafenib in combination with sildenafil (32). 
This study was a non -cancer study, which tr eated patients with pulmonary hypertension 
with sorafenib and prostanoid therapy, half of whom were also on chronic sildenafil. No 
grade 3 or 4 drug -related toxicities were reported.  
Children under the age of 18 will be excluded from study. There are no p ublished reports 
regarding the safety of sorafenib at the fixed dose of 400 mg orally, twice a day, in the 
pediatric population, and evaluating the safety of full dose sorafenib in the pediatric 
population is beyond the scope of the study.  
In patients with  progressive high-grade glioma , survival time is generally short. Six-month 
PFS will be used as the primary endpoint in the study. This endpoint has been accepted by 
the FDA as a reasonable endpoint in recurrent or progressive GBM, and a positive 6 -
month P FS led to the approval of bevacizumab as second -line therapy in this disease.  
MCC Protocol #:  MCC -14816   9 Version #: 1 2 
  Version Date: 04/22/2021 1.8 Correlative Studies Background  
Molecular profiling has identified various phenotypes of GBM. It has already been shown 
that the methylation status of the MGMT promoter is an impo rtant prognostic factor in 
predicting survival with alkylating therapy (33). More recently, The Cancer Genome Atlas 
(TCGA) Network catalogued recurrent genetic abno rmalities in GBM, and established the 
existence of 4 subtypes ( proneural, neural, classical, and mesenchymal) (34). Aberrations 
and gene expression of EGFR , NF1, and PDGFRα/IDH1  each define classical, 
mesenchymal, and proneural, respectively. Gene signatures of normal brain cell types 
showed a strong relation between subtypes and different neural lineages. Additionally, 
response to aggressive therapy differs by su btype with greatest benefit in classical and no 
benefit in proneural (34). Given the differences in sensitivity to the combination of sorafenib 
and valproic acid  in preclinical models, it will be important to characterize patient tumors, 
as this combination may be effective in one  subtype of GBM but ineffective in another. 
PDGFRα is a target of sorafenib, and expression of this protein may predict drug efficacy. 
This study will evaluate PDGFRα levels in tumor specimens by immunohistochemistry 
(IHC), and correlate this sorafenib dru g target to response. Consideration will be given to 
gene expression profiling at the conclusion of the study, based on responses to therapy. 
This may help to further characterize the patient population to be targeted in a phase 3 
study.   
1.9 Rationale for Ada ptive Design  
All patients with recurrent or progressive high-grade glioma  will be eligible for the study. 
Sorafenib is a multikinase inhibitor, with a wide variety of cellular effects. Not enough is 
known about the  in vivo  mechanisms of action and resistan ce to the drug to justify initial 
exclusion of molecular subtypes of high-grade glioma . There will be an interim analysis, 
however; at which point the decision will be made whether or not to continue with all 
subtypes of high-grade glioma , based on pre -specified efficacy criteria. If efficacy criteria 
are not met for the combined group, the study will continue with only patients who have 
PDGFRα expressing tumors, since PDGFRα is a target of sorafenib and this is the most 
promising subgroup in preclinical mo dels. A second interim analysis will be performed 
once enough patients with PDGFRα expressing tumors have been accrued, to determine if 
the drug combination is worth pursuing in this specific patient population.  
2 OBJECTIVES  
2.1 Primary Objective  
2.1.1  Determine the e fficacy of the combination of sorafenib, valproic acid, and sildenafil, 
in terms of 6 -month PFS in high-grade glioma . 
2.2 Secondary Objectives  
2.2.1  Determine the efficacy of the combination of sorafenib, valproic acid, and sildenafil, 
in terms of 6 -month PFS in hig h-grade glioma patients who are evaluable for 
response and who have tumors that express PDGFRα.  
2.2.2  Evaluate the overall response rate , based on Response Assessment in Neuro -
Oncology (RANO) criteria  or Macdonald criteria , to the drug combination in patients 
MCC Protocol #:  MCC -14816   10 Version #: 1 2 
  Version Date: 04/22/2021 who are evaluable for response  (those who express PDGFRα and thos e who do 
not). 
2.2.3  Evaluate the overall response rate, based on RANO or Macdonald criteria, to the 
drug combination in PDGFRα expressing tumors  in patients who are evaluable for 
response . 
2.2.4  Determine the efficacy of the drug combination, in terms of 12 -month sur vival and 
median overall survival in patients who are evaluable for response  (those who 
express PDGFRα and those who do not) . 
2.2.5  Determine the efficacy of the drug combination, in terms of 12 -month survival and 
median overall survival in high -grade glioma pat ients who are evaluable for 
response and who have tumors that express PDGFRα .  
2.2.6  Evaluate the safety and toxicity of the drug combination.  
  
  
  
3 STUDY DESIGN  
3.1 General Description  
The study is a single -center, open -label phase 2 study, with a n early stopping rule in place 
for safety . The trial will include patients with recurrent or progressive high-grade glioma . 
The trial will be c onduct ed in an adaptive design, with a  Simon ’s mini-max 2-stage design 
(35) incorporating an interim analysis for efficacy.  If efficacy endpoints are not reached, the 
trial focus will be narrowed to include only  the subgroup of  patients whose tumors express 
PDGFRα.  The trial will continue with this cohort in a second Simon’s mini -max 2-stage 
design, with an additional interim  efficacy  analysis of this subgroup.   
3.2 Primary Endpoint  
Proportion of  patients  evaluable for response , regardless of tumor PDGFR status , with 6 -
month  PFS defined as the time from the first day a patient receives study treatment until 
time of progression per RANO or Macdonald criteria or death, whichever occurs first.  
3.3 Secondary Endpoints  
3.3.1  Proportion of  patients  evaluable for response , with tumors that e xpress PDGFRα, 
with 6 -month PFS defined as the time from the first day a patient receives study 
treatment until time of progression per RANO or Macdonald criteria or death, 
whichever occurs first.  
3.3.2  Overall response rate  (CR+PR), using  RANO or Macdonald cri teria, in patients 
evaluable for response regardless of tumor PDGFR status  

MCC Protocol #:  MCC -14816   11 Version #: 1 2 
  Version Date: 04/22/2021 3.3.3  Overall response rate  (CR+PR), using  RANO or Macdonald criteria, in  patients who 
are evaluable for response and who have tumors that express PDGFRα.  
3.3.4  Proportion of patients  evaluable  for response , regardless of tumor PDGFR status, 
who are alive at 12 months  after the first day a  patient receiv es study treatment. OS 
defined as the time from the first day a patient receives study treatment until death 
by any cause.  
3.3.5  Proportion of patient s evaluable for response with tumors that express PDGFRα 
who are alive at 12 months  after the first day a patient receiv es study treatment. OS 
defined as the time from the first day a patient receives study treatment until death 
by any cause.  
3.3.6  AEs using NCI Common Terminology Crite ria for Adverse Events, Version 4.0 
(CTCAE v4.0) . 
  
  
. 
4 PATIENT SELECTION  
4.1 Inclusion Criteria  
A patient  must  meet all of the following inclusion criteria to be eligible to participate in the 
study:  
4.1.1  Pathologically confirmed high-grade glioma (WHO grade 3 or 4) , with documented 
CT or MRI progression or recurrence . Biopsy is also an acceptable method of 
confirming progression.  If initial tumor was grade 2 glioma, histological confirmation 
of high -grade recurrence is required.  
• After first interim analysis, if the study proceeds to enrollment of selected 
patie nts (only those who have PDGFRα -positive tumors), patient s will be pre -
registered for PDGFRα  analysis and registered to the combination treatment 
schema only if PDGFRα -positive and all other enrollment criteria are met.  
4.1.2  Measurable or evaluable disease by R ANO  (MRI) or Macdonald (CT) criteria  (see 
Section 10.2). 
4.1.3  Fixed or decreasing dose of corticosteroids (or no corticosteroids) for at least 1 
week prior to cycle 1 day 1 . 
4.1.4  Age ≥ 18 years . 
4.1.5  At least 12 weeks since th e completion of radiation therapy  to a total of ≥ 50 Gy .  

MCC Protocol #:  MCC -14816   12 Version #: 1 2 
  Version Date: 04/22/2021 4.1.6  ECOG performance status of 0,  1, or 2  (Appendix 1 ). 
4.1.7  Clinical laboratory parameters:  
• WBC ≥ 3,000/mm3 
• ANC ≥ 1 ,500/mm3 
• Platelets ≥ 100,000 /mm3 
• Hgb ≥ 8.5  g/dL 
• AST, A LT ≤ 3 x upper limit  of normal  (ULN)  for the laboratory  
• Total bilirubin ≤ 1.5 x ULN for the laboratory (total bilirubin criteria may be waived 
if a patient  has documented Gilbert’s disease)  
• Creatinine clearance ( CrCL) ≥ 30 mL/min as calculated  by the standard 
Cock croft-Gault equation  (Appendix 2 ) 
4.1.8  Women of childbearing potential must have a negative serum pregnancy test 
performed within 7 days prior to the start of treatment.  
4.1.9  Women of childbearing potential and men must agree to use a me dically accepted 
form of birth control for the duration of study participation  and for 2 months following 
completion of study treatment.  
4.1.10  Ability to understand and the willingness to sign a written informed consent 
document.  
4.2 Exclusion Criteria  
A patient  who meets any of the following exclusion criteria is ineligible to participate in the 
study : 
4.2.1  Investigational agent within 4 weeks of first dose of study treatment.  
4.2.2  Prior bevacizumab or tyrosine -kinase inhibitor .  
4.2.3  History of allergic reactions  or intolerance  to any of the required agents on the 
study . 
4.2.4  Any condition that would prohibit patient from initiating valproic acid. Current or prior 
valproic acid treatment is allowed  (do not need to be  ≥ LLN for laboratory for 
enrollment). See Section  6.2.7  for details on valproic acid titration prior to initiation of 
study therapy.  
4.2.5  Seizure disorder necessitating the use of EIAED s. Efforts may be made by the 
treating physician to change the antiepileptic drug from  another agent to valproic 
acid or non -EIAED prior to excluding the patient from study.  
4.2.6  Contraindication to antiangiogenic agents, including:  
• Bronchop ulmonary hemorrhage/bleeding event ≥ grade 2 (NCI Common 
Terminology Criteria for Adverse Events [ CTCAE ] version 4 .0) within 4 weeks or 
less prior to  first dose of study drug.  
• Any other hemorrhage/bleeding event ≥ grade 3 (CTCAE v4 .0) within 4 weeks 
or less prior to  first dose of study treatment.  
MCC Protocol #:  MCC -14816   13 Version #: 1 2 
  Version Date: 04/22/2021 • Radiol ogical  evidence of any intracranial hemorrhage within the 4 weeks or less 
prior to first dose of study treatment.  
• History of significant intratumoral, intracerebral, or subarachnoid hemorrhage.  
• Serious non -healing wound, ulcer, or bone fracture.  
• Documented  bowel perforation within 6 months of the start of study treatment.  
4.2.7  Major surgery within 2 weeks of the start of study treatment, or ongoing 
complications from surgeries performed previously.  
4.2.8  Clinically significant cardiac disease, including major cardiac  dysfunction, such as 
uncontrolled angina,  clinical  congestive heart failure with  New York Heart 
Association  (NYHA ) class III or higher  (Appendix 3 ), ventricular arrhythmias 
requiring anti -arrhythmic therap y, recent (within 6 m onths) myocardial infarction or 
unstable coronary artery disease . 
4.2.9  Systolic blood pressure (BP) > 160 mm Hg or diastolic pressure > 100 mm  Hg 
despite  optimal medical management.  
4.2.10  History of priapism . 
4.2.11  Known history of retinitis pigmentosa.  
4.2.12  Known mitochondrial  disorder  caused by mutations in mitochondrial DNA 
polymerase γ . 
4.2.13  Arterial thromboembolic or embolic events such as myocardial infarction, 
cerebrovascular accident, including transient ischemic attacks within  6 months prior 
to first study treatment.  
4.2.14  Serious  uncontrolled infection > grade 2  (CTCAE v4 .0).  
4.2.15  Known HIV positivity.  
4.2.16  Unable to swallow medication or suspected malabsorption.  
4.2.17  Patients on chronic nitrate therapy  or alpha -blockers . 
4.2.18  Exclude persons who require ongoing administration of STRONG CYP 3A4 inhib itors 
and/or STRONG CYP3A4 inducers  and/or STRONG CYP2C9 inhibitors . Examples 
of clinical inhibitors and clinical inducers for P450 -mediated metabolisms  and 
classification of strong, moderate , and weak interac tions are available through the 
FDA website, Ta ble 3-2 and 3-3: 
http://www.fda. gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Dr
ugInteractionsLabeling/ucm093664.htm  
4.2.19  Women who are pregnant or nursing.  
4.2.20  Persistent h eart rate  (HR)  < 50 or >  120 beats per minute  (bpm) . 
4.2.21  QTc > 480  ms (grade 2 or greater)  on screening E CG*. 
MCC Protocol #:  MCC -14816   14 Version #: 1 2 
  Version Date: 04/22/2021 * If baseline QTc on screening E CG meets exclusion criteria on screening 
assessment:   
- Check potassium  and m agnesium  levels  
- Correct any identified hypokalemia and/or hypomagnes emia and repeat 
ECG to confirm exclusion of  patient due to QTc  
• For patients with a HR 60-100 bpm, no manual read of QT is required.  
• For patients with baseline HR < 60 or > 100  bpm, manual read of QT by 
cardiologist is required using Fridericia correction . 
4.2.22  Other condition(s) that in the opinion of the investigator might compromise the  
objectives of the study.  
5 STUDY ENTRY AND WITH DRAWAL  PROCEDURES  
5.1 Registration Procedures  
To registe r a patient, the study team will provide the following to the registrar at VCU 
Massey Cancer Center   
• Registration cover sheet  
• Completed eligibility checklist  
• Signed & dated informed consent  form  
The registrar will complete the registration process by assigning a study ID number and 
forwarding the “Confirmation of Registration” form to the registering study team.  
No patient  may begin study treatment until the Confirmation of Registration as signing a 
study ID number has been received from the registrar. The registering study team will 
enter into  the OnCore database the patient ’s initial enrollment data (demographics, 
consent, eligibility, on study, treatment assignment) within 24 hours of reg istration and 
before treatment begins.  
5.2 Study Discontinuation  Procedures  
5.2.1  A patient may decide to withdraw from study participation at any time . 
5.2.2  Patients will be removed from study treatment and enter into the follow -up phase 
when  any of the criteria listed in Section 7.6 “Duration of Therapy”  applies.  
5.2.3  A patient may be removed from the study follow -up phase and be taken off study for 
any of the following reasons:  
• Investigator determination that discontinuation is in a patient’s best medical 
interest  
• Withdrawal of support of study sponsor  

MCC Protocol #:  MCC -14816   15 Version #: 1 2 
  Version Date: 04/22/2021 5.2.4  The reason for study removal and the date the patient was removed must be 
documented in the source documents and the OnCore case report forms (CRF s). 
6 TREATMENT PLAN  
6.1 Baseline Tests  and Procedures  
Refer to Section  12, Study Calendar , for the screening tests and procedures that are 
required prior to treatment and/or registration, and for the timing of these events relative to 
the start of combination treatment.  
6.2 Schedule  
The treatment schedule is combined sorafenib, valproic acid, and sildenafil , administered 
orally, twice daily continuously. A c ycle consists of 4 weeks. The first c ycle begins once 
therapy begins with all 3 agents —after, if necessary,  titration of valproic acid dosage , 
described in Section  6.2.7 . Titration of valproic acid may occur as a matter of clinical 
preference, prior to study enrollment.  
Study d rug therapy is taken on an empt y stomach , that is, at least 1 hour  before or 2 hours 
after eating , due to absorption characteristics of sorafenib.  
The first 6  patient s evaluable for qualifying toxicity assessment will be treated as a safety 
lead-in; enrollment will be gated (the first 3 evaluable patient s must complete 4 weeks of  
the combination  therapy bef ore the next 3 patient s start combination treatment on protocol ) 
and patient s will undergo  weekly evaluations  for qualifying toxicities  (Section 6.4.2 ) during 
the first 4 weeks of combination therapy.  
6.2.1  Initiation of sorafenib and sildenafil will not take place until valproic acid levels are ≥ 
LLN for the laboratory , which generally takes 5 -7 days  after initiation .  
6.2.2  Valproic acid will be administered orally, generally twice daily. The tablets or 
capsules  should be swallowed without chewing to avoid local irritation of the mouth 
and throat. Patient s who experience gastrointestinal  irritation may benefit from 
administration of the drug with food or by slowly building up the dose from an initial 
low level.  
6.2.3  If a patient  is already on valproic acid and blood levels are ≥ LLN for the labor atory , 
no further titration is necessary.  
6.2.4  If a patient presents for evaluation for this study and are at risk for seizures, the 
patient may be started on valproic acid.  
6.2.5  If a patient is already on non-valproic acid antiepileptic therapy, they may be 
transit ioned to valproic acid , as a matter of clinical preference, prior to enrollment to 
obtain levels ≥ LLN for the laboratory prior to discontinuing the original antiepileptic 
therapy.   
6.2.6  Patient s with disease recurrence require routine maintenance on anti epileptic 
therapy. If a patient  presents for study evaluation before initiation o f antiepileptic 
MCC Protocol #:  MCC -14816   16 Version #: 1 2 
  Version Date: 04/22/2021 medica tion, patient  may start valproic acid titration to ≥ LLN for the laboratory as a 
matter of clinical care.  
6.2.7  Valproic acid titration: Titration to levels ≥ LLN for the laboratory generally takes 5 -7 
days. The FDA recommends that valproic acid doses start at 10-15 mg/kg/day. If a 
patient is already on a stable dose of valproic acid, the drug does not need to be 
titrated unless the dose  is less than the  LLN. 
6.2.8  Sorafenib is dosed at 400 mg orally, twice daily, continuously. Subsequent dose 
modifications are allowe d based on toxicity assessment.  
6.2.9  Sildenafil is dosed at 50 mg orally, twice daily , continuously. Subsequent dose 
modifica tions are allowed based on toxicity assessment.  
6.3 Radiographic Evaluations  
6.3.1  MRI of the brain obtained within 3 weeks prior to entry into th e protocol can be used 
as baseline staging evaluation. In the event that MRI scans cannot be performed, 
contrast -enhanced CT scans can  be used. If scans were obtained from another 
institution, copies should be obtained  and maintained  in the research files .  
6.3.2  A reasonable dose of corticosteroids will be determined on clinical grounds for each 
patient. An effort will be made to keep the patient on this steroid dose for at least 5 
days prior to the next MR I or contrast -enhanced CT scan. If it is not possible to  keep 
the steroid dose constant for 5 days then the MR I scan will be  delayed until  the dose 
has been stable for 5 days.  
6.4 Toxicity Assessments  
6.4.1  Toxicity Grading  
Adverse events (AEs) will be characterized and graded according to NCI CTCAE  
version 4 .0. See Section 8. 
6.4.2  Qualifying Toxicities for the Safety Lead -In and Safety Stopping Rule  
Qualifying toxicities for the safety lead -in are evaluated weekly during the first 4 
week s of combination treatment for each of the f irst 6 patient s deemed evaluable for 
qualifying toxicity for the safety lead -in (see Section 10.1). 
Qualifying toxicities for the safety stopping rule are evaluated regularly  during  the 
first 4 -week c ycle of combination trea tment for patients deemed evaluable for  the 
early stopping rule  (see Section 10.1). 
Qualifying toxicities are  defined as any of the following  that are possibly, probably, 
or definitely related  to drug therapy:  
Any grade ≥ 3 toxicity , except the following:  
• nausea, vomiting, or diarrhea in the absence of adequate prophylaxis and/or 
responsive to medical management  
• grade 3 thromboembolic event  
MCC Protocol #:  MCC -14816   17 Version #: 1 2 
  Version Date: 04/22/2021 • grade 3 hyperglycemia  
• grade 3 PPE (hand -foot syndrome ) 
• fatigue responsiv e to medical management  
• grade 3 hypertension  
• electrolyte abnormalities that, once corrected, can be maintained with oral 
repletion  
• grade 3 anemia, platelets, neutrophils, WBC, lymphocytes, febrile neutropenia  
6.4.3  See Section 8.5 for AE and qualifying toxicity reporting procedures.  
7 DOSE MODIFICATIONS  
If the toxicity is not covered in  Table 1, Table 2, Table 3, or Table 4, use the following 
general guidelines:  
• Option to modify for grade ≥ 1 toxicity  
• Recommendation to consider modif ication  for grade ≥ 2 non -hematologic toxicity , 
other than PPE (see sorafen ib dose -modification  guidelines below)  
• Requirement to modify for grade ≥ 3 non -hematologic toxicity  
• Requirement to modify for grade 4 toxicity  
Study treatment modification cons ists of dose omission and/or schedule adjustment of 1 or 
more agents as clinical ly appropriate  and as described below. In general, agent(s) should be 
omitted pending resolution of toxicity to ≤ grade 1 and then resumed at the same or a lower 
dose  or frequency .  
Should the occasion arise that one or more of the study agents need to be discontinued due 
to dose modification requirements, patient s may continue on study at investigator discretion, 
taking single - or dual -agent study drug treatment, with the following exception: if both 
valproic acid and sorafenib must be permanently stopped,  study treatment will be 
discontinued.  
Patients are not required to be removed from study treatment for a qualifying toxicity 
(Section 6.4.2 ). Removal from the study treatment for safety reasons may be considere d at 
the treating physician’s discretion, based on the severity/type of toxicity.  
7.1 Sorafenib  
Sorafenib dose  reduc tions (to be followed decrementally  in this order) :  
• 400 mg twice daily  
• 400 mg daily  
• 200 mg daily  
• 200 mg twice daily dosed every other day  
• If cannot tolerate lowest sorafenib dose, discontinue  sorafenib  
MCC Protocol #:  MCC -14816   18 Version #: 1 2 
  Version Date: 04/22/2021 If toxicities leading to modification resolve to ≤ grade  1, the sorafenib dose may be 
escalated  in increments of 200 mg per day  after cycle 1  but not beyond a patient’s 
enrollment dose . 
7.1.1  Sorafenib Dose Modifications  
Table 1. Sorafenib Dose Modifications  
Toxicity  Sorafenib Modifica tion 
Cardiac  
Grade ≥2 acute coronary 
syndrome (myocardial 
ischemia) or Grade ≥2  
myocardial infarction  Discontinue sorafenib  permanently . 
Heart failure  Grade 3  • Interrupt until ≤ grade 1; upon resumption, decrease by 1 dose 
level. 
• If no recovery after 30 day interruption, discontinue sorafenib 
permanently unless patient is deriving clinical benefit; confer 
with PI.  
Grade 4  Discontinue sorafenib permanently.  
Skin and Subcutaneous Disorders  
Palmar -plantar 
erythrodysesthesia 
syndrome (PPE) (h and-foot 
synd rome ) See Table 2 ‘Sorafenib Dose Reduction Guidelines for PPE 
(Hand -Foot Syndrome ).’ 
Grade 2 rash acneiform  At investigator’s discretion, consider holding and/or reducing 
sorafenib to the next lower dose . 
Grade 3 or grade 4  
rash acneiform  Hold sorafenib . 
• Re-evaluate at least weekly until resolution to ≤ grade 1 or 
tolerable grade 2 . 
• Re-start sorafenib at one dose reduction . 
• If toxicity persists > 14 days, discontinue sorafenib . 
• Patients with grade 4 acneiform ra sh related to sorafenib may 
be taken off sorafenib at investigator’s discretion . 
Stevens -Johnson syndrome 
or toxic epidermal 
necrolysis  Discontinue sorafenib if Stevens -Johnson Syndrome or toxic 
epidermal necrolysis are suspected.  
Gastrointestinal Disord ers 
Perforation (esophageal, 
gastric, colonic, duodenal, 
ileal, jejunal, rectal, or small 
intestine)  Discontinue sorafenib  permanently .  
MCC Protocol #:  MCC -14816   19 Version #: 1 2 
  Version Date: 04/22/2021 Investigations  
Grade ≥ 3 ALT increase  in 
the absence of another 
cause  
or 
 
AST or ALT >3x ULN with 
bilirubin >2xULN in the 
absence of another cause;  
 
or 
 
Grade ≥ 1 Alkaline 
phosphatase in the 
absence of known bone 
pathology with grade ≥ 
grade 2 bilirubin increase;  
 
or  
 
any 1 o f the following  
INR ≥ 1.5, ascites and/or 
encephalopathy in the 
absence of underlying 
cirrhosis or other organ 
failure related to drug -
induced liver injury  
 Discontinue sorafenib permanently.  
 
Lab abnormalities - not 
clinically significant  
 
Note: For clin ically 
significant lab abnormalities 
follow the dose modification 
guidelines for “All Other 
Non-Hematologic  
Toxicities.”  Continue sorafenib an d institute supportive measures. At 
investigator’s discretion, consider holding and/or reducing 
sorafenib to the next lower dose . 
MCC Protocol #:  MCC -14816   20 Version #: 1 2 
  Version Date: 04/22/2021 Grade 3 electrocardiogram 
QT corrected interval 
prolonged  See also Section 7.4.8  
Hold sorafenib  
• Check and immediately administer pota ssium to achieve 
levels of ≥ 4 and magnesium to levels of ≥ 2.  
• Consider chronic oral supplementation of potassium and/or 
magnesium.  
• Review with principal  investigator prior to patient’s  next 
scheduled treatment, considering the following options:  
o STOP sor afenib until QTc recovers to pre -study 
treatment baseline (grade 1 or less, or ≤ 480ms).  
o When QTc returns to baseline, reinitiate 
sorafenib cautiously, with additional QTc 
monitoring at earliest possible follow -up 
opportunity, but no more than 8 days from 
reintroduction of sorafenib.  
o If QTc prolongation event felt attributable to 
sorafenib, reduce sorafenib to the next lower 
dose.  
• For recurrent QTc grade 3 felt attributable to sorafenib despite 
dose reduction, consider permanent discontinuation of 
sorafenib . 
Grade 4 electrocardiogram 
QT corrected interval 
prolonged  Discontinue sorafenib. Do not restart.  
Nervous System Disorders (potentially reflective of cardio -toxicity)  
Grade 2 pre -syncope or 
grade 3 syncope  See also Section 7.4.8  
• Obtain ECG for cardiology review/consultation.  
• Check and immediately administer potassium to achieve 
level of ≥ 4 and magnesium to level ≥ 2. 
• If ECG shows new dysrhythmia or QTc ≥ grade 2 (> 480ms), 
hospitalize for monitoring with C ardiology consultation.   
• STOP sorafenib until any potassium and magnesium 
abnormalities are corrected, symptoms resolved and QTc 
returns to grade 1 or less ( ≤ 480ms).  
• Reintroduce sorafen ib cautiously, with input from C ardiology 
and with additional QTc eval uation, either concurrent with 
reintroduction or at earliest possible follow -up opportunity 
and no more than 8 days from reintroduction.  
• If event felt attributable to sorafenib, reduce sorafenib to the 
next lower dose.  
• Consider chronic oral supplementation  of potassium and/or 
magnesium.  
• For recurrent syncope or near -syncope felt attributable to 
sorafenib, consider permanent discontinuation of sorafenib.  
Vascular Disorders  
Hypertension  See Table 3 ‘Management of Hy pertension. ’ 
All Other Non -Hematologic Toxicities  
Grade ≥2 hemorrhage 
(requiring medical 
intervention)  Discontinue sorafenib permanently.  
MCC Protocol #:  MCC -14816   21 Version #: 1 2 
  Version Date: 04/22/2021 Any g rade 2 non-
hematologic toxicit y that is 
persistent , intolerable , or 
unresponsive to optimal 
management  At the treating investigator’s discretion, consider holding  or 
continuing treatment at 1 dose reduction.  
Grade 3   1st occurrence:  
• Hold sorafenib until resolution to ≤ grade  2 or baseline . 
• When resuming sorafenib, decrease the sorafenib dose 
by one dose reduction . 
•  If toxicity  persists  >14 days of treatment delay , 
discontinue sorafenib.  
No improvement within 7 days; or 2nd or 3rd occurrence:  
• Hold sorafenib until resolution  to ≤ grade 2 or baseline . 
• When resuming sorafenib, decrease the sorafenib dose 
by 2 dose red uctions.  
•  If toxicity  persists  >14 days of treatment delay , 
discontinue sorafenib  
4th occurrence:  
• Hold sorafenib until resolution  to ≤ grade 2 or baseline . 
• When resuming sorafenib, decrease the sorafenib dose 
by 3 dose reductions.  
•  If toxicity  persists  >14 days of treatment delay , 
discontinue sorafenib  
Grade 4  Discontinue sorafenib  permanently.  
MCC Protocol #:  MCC -14816   22 Version #: 1 2 
  Version Date: 04/22/2021 7.1.2  Sorafenib Dose Modification  Guidelines and Management for PPE ( Hand -Foot 
Syndrome )  
Table 2. Sorafenib Dose Reduction Guidelines for PPE  
Grade  Occurrence  Action  
Grade 1  1st occurrence or 
recurrence  Continue sorafenib and institute 
supportive measures for 
symptomatic relief.*  
Grade 2: Moderate and painful 
skin changes of hands and/or 
feet such as peeling, blisters, 
bleeding, hyperkeratosis,  
erythema, swelling; and/or any 
such changes that are limiting 
instrumental activities of daily 
living (preparing meals, 
shopping for groceries, using the 
telephone, managing money, 
etc). 1st  occurrence  Decrease sorafenib dose by one  
dose level and instit ute or continue 
supportive measures for 
symptomatic relief.*  
 
If no improvement within 7 days, see 
below.  
No improvement 
within 7 days  Stop sorafenib treatment until toxicity 
resolves to grade 0 -1. When 
resuming treatment,  continue at 
ongoing dose redu ction .  
Institute or continue supportive 
measures for symptomatic relief.*  
Recurrence beyond 
1st occurrence  Stop sorafenib treatment until toxicity 
resolves to grade 0 -1. When 
resuming treatment,  decrease 
sorafenib by 1 dose level .  
Institute or continue  supportive 
measures for symptomatic relief.*  
Grade 3: Severe and painful skin 
changes of the hands and/or 
feet, such as moist 
desquamation, ulceration, 
blistering, bleeding, 
hyperkeratosis, erythema, 
swelling; and/or any such severe 
changes or pain that are limiting 
self-care activities of daily living 
(bathing, dressing, feeding self, 
using toilet, taking medications 
or becoming bedridden).  1st or 2nd occurrence  Stop sorafenib treatment until toxicity 
resolves to grade 0 -1. When 
resuming tr eatment, decr ease 
sorafenib by one  dose level.  
Institute or continue supportive 
measures for symptomatic relief.*  
3rd occurrence  Discontinue sorafenib treatment.  
*See also Section 7.4.7 . 
7.1.3  Sorafenib Dose Modification Guidel ines and Management for Hypertension  
The management of hypertension  related to sorafenib , including the choice of 
antihypertensive medication, will be performed according to the treating physician’s 
usual practice.  
Every effort should be made to control BP  by medical means other than sorafenib 
dose modification. If necessary, follow the sorafenib dose reduction instructions in 
Table 3. 
MCC Protocol #:  MCC -14816   23 Version #: 1 2 
  Version Date: 04/22/2021 Table 3. Management of Hypertension  Related to Sorafenib  
Grade  Antihypertensive Therapy  Sorafenib Dosing  
Grade 1  
Prehypertension  
Systolic BP 120 -139 mmHg  
or  
Diastolic BP 80 -89 mmHg  None  • Continue sorafenib  
• Consider increasing BP 
monitoring  
Grade 2  
Asymptomatic and diastolic 
BP 90 -99 mmHg  Treat w ith the aim to  
achieve diastolic BP  < 90 
mmHg  
• If BP previously WNL , 
start antihypertensive  
• If patient is already on 
antihypertensive 
medication, increase the 
dose  Continue sorafenib and 
increase BP monitoring  
Grade 2  
Symptomatic or persistent  
 
or 
 
Grade 2  
Symptomatic increase in 
diastolic BP by > 20 mmHg 
(diastolic)  or > 140/90 
mmHg if previously within 
normal limits  
 
or 
 
Grade 3  
Systolic BP ≥ 160 mmHg  
or 
Diastolic BP ≥ 100 mmHg  
or 
More than one 
antihypertensive medication 
or indication for more 
intensive therapy than 
previously used  Treat with the aim to 
achieve diastolic BP < 90 
mmH g 
Start antihypertensive 
medication  
and/or  
Increase current 
antihypertensive medication  
and/or  
Add additional hypertensive 
medications  • Omit sorafenib until 
diastolic BP ≤  90 mmHg, 
and if sy mptomatic, until 
symptoms resolve  
• When sorafenib is 
restarted , resume at 1 
dose reduction step  
Grade 4  
Life-threatening 
consequences (eg, 
malignant hypertension , 
transient or permanent 
neurologic deficit, 
hypertensive crisis)  Per treating physician  Discon tinue  sorafenib 
permanently.  
* If BP remains controlled for at least one cycle, dose escalation, up to the enrolled dose 
level , is permitted at the investigator’s discretion.  
MCC Protocol #:  MCC -14816   24 Version #: 1 2 
  Version Date: 04/22/2021 7.2 Sildenafil  
Sildenafil dose  reductions  (to be followed decrementally  in this ord er): 
• 50 mg twice daily  
• 25 mg twice daily  
• 25 mg once daily  
• If cannot tolerate lowest sildenafil dose, discontinue  sildenafil  
Sildenafil may be omitted  for short periods at the treating physician’s discretion, if it is 
believed that sildenafil is contributi ng to excess toxicity. If toxicities resolve to ≤ grade 1, 
the sildenafil dose may be escalated at  the treating physician’s discretion  but not beyond a 
patient’s enrollment dose . 
The following toxicities require immediate discontinuation of sildenafil therapy:  
• Prolonged erection for more than 4 hours  
• Sudden loss of vision in one or both eyes  
• Sudden decrease or loss of hearing  
7.3 Valproic Acid  
If toxicity is observed that is thought to be due to valproic acid then serum valproate levels 
should be obtained. If supratherapeutic valproate levels are observed (a s described in 
Section 1.7) temporary interruption of valproate may be indicated until toxicity resolves to 
grade 1 or less. Upon resolution of toxicity, a repeat serum valproate level should be 
obtained. Resump tion of valproic acid at a reduced dose to achieve a lower serum 
valproate level should be considered. In the setting of hypoalbuminemia , the serum 
valproate level may be falsely elevated and a free valproate level may be required.  
MCC Protocol #:  MCC -14816   25 Version #: 1 2 
  Version Date: 04/22/2021 Table 4. Vaproic Acid Dose Modifications  
Toxicity  Valproic Acid Modification  
General D isorders: Hypothermia  
Lethargy, confusion, coma, 
significant alterations in major 
organ systems (cardiovascular 
and respiratory) may signal 
hypothermia  Consider holdin g valproic acid while evaluating serum 
valproic acid levels. Blood ammonia level may be evaluated 
at investigator discretion.  
Grade 2 or greater h ypothermia  Consider discontinuing valproic acid. Discuss with principal 
investigator.  
Investigations: Othe r – Hyperammonemia  
Sympto matic elevated 
ammonia level. Ammonia 
measured only as clinically 
indicated for clinical findings of 
unexplained lethargy, vomiting 
or changes in mental status.  Consider holding valproic acid while measuring serum 
valproic acid an d ammonia levels. Consider evaluation for 
underlying urea cycle disorder and discontinuing valproic acid 
for elevated ammonia level. Discuss with principal 
investigator.  
If liver toxicity is suspected:  
• Discontinue valproic acid  
• Consider supplementation wi th L-carnitine  
Investigations:  Hepatotoxicity  
Grade 3 or grade 4  
AST or ALT increase  Consi der holding valproic acid while  under evaluation to rule 
out hepatic dysfunction.    
Consider liver ultrasound, hepatology consult, tests of hepatic 
function (such as bilirubin, INR, GGT, ammonia).  
Consider s upplementation with L -carnitine.  
If no alternative explan ation for transaminitis can be 
determined (such as viral hepatitis, progressive underlying 
malignancy), discontinue valproic acid.  
Gastrointestinal Disord ers 
Abdominal pain, nausea, 
vomiting and/or anorexia that 
are not attributable to other 
causes can signal pancreatitis 
and require prompt medical 
evaluation  Consider holding valproic acid while under evaluation and 
ruling out pancreatitis.  
Pancreatitis  Discontinue valproic acid .  
 
Note: Elevations in lipase are very common in patients taking 
sorafenib. A diagnosis of pancreatitis should not be made 
solely based on abnormal laboratory values.  
Valproic acid should be immediately discontinued in the presenc e of significant hepatic 
dysfunction, suspected or apparent . 
Patients should be monitored for the emergence or worsening of depression, suicidal 
thoughts or behavior, and/or unusual changes in mood or behavior.  
Significant bleeding or coagulopathy is an in dication for reduction of the dosage or 
discontinuation of valproic acid.  
MCC Protocol #:  MCC -14816   26 Version #: 1 2 
  Version Date: 04/22/2021 7.4 General Concomitant Medication and Supportive Care Guidelines  
(see also Section 9) 
7.4.1  Fluids should be administered as indicated to prevent/ treat dehydration. Maintain  
appropriate electrolyte balance including correction of hypokalemia and  
hypomagnesemia,  and hypophosphatemia,  if possible, prior to and during study 
treatment. In those patient s who demonstrate electrolyte abnormalities , oral 
supplementation should be considered as  a standard supportive measure to keep 
magnesium  levels at  ≥ LLN for the laboratory , potassium levels at ≥ LLN for the 
laboratory , and phosphorus levels at or above 2.4 mg/dL . 
7.4.2  Clinically significant diarrhea should be m anaged aggressively to prevent electrolyte 
abnormalities and dehydration.  
7.4.3  Concurrent administration of other anti -neoplastic agents with the study combination 
regimen is prohibited . 
7.4.4  Concurrent administration of organic nitrates or alpha -blockers with the study 
combination regimen is  prohibited . 
7.4.5  Cautionary statements about other concurrent medications:  
Addition of any STRONG CYP inhibitors and/or inducers per examples on the FDA 
website 
(http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D
rugInteractionsLabeling/ucm093664.htm ) during study participation should prompt 
treating investigator awareness of possible interactions. Specifically:  
• Caution should be observed if sorafenib is to be coadministered with CYP3A4 
inducers such as rifampin, rifampicin, St. John’s wort, phenytoin, carbamazepine, 
phenobarbital, and dexamethasone (for reference see  
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources
/DrugInteractionsLabeling/ucm093664.htm ) may increase metabolism of 
sorafe nib, decreasing sorafenib plasma concentrations  
• Caution should be observed if sildenafil is to be coadministered with CYP3A4 or 
CYP2C9 inhibitors (for reference see 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources
/DrugInteractionsLabeling/ucm093664.htm ) 
7.4.6  Caution should be observed if valproic acid is to be coadministered with any of 
the following: aspirin, ca rbapenem antibiotics (ertapenem, imipenem, 
meropenem), rifampin . 
7.4.7  PPE (h and-foot syndrome )  
Biopsy specimens of patients with PPE secondary to tyrosine kinase inhibition show 
hyperkeratosis, keratinocyte necrosis, and dermal inflammation. Recommended 
manage ment strategies for skin toxicities consistent with PPE are summarized in 
the following sections:  
MCC Protocol #:  MCC -14816   27 Version #: 1 2 
  Version Date: 04/22/2021 7.4.7.1  PPE Prevention  
• Before initiating treatment with sorafenib, check the condition of the 
patient’s hands and feet. Suggest a manicure/pedicure, when indicated. 
Recommend use of a pumice stone for callus or rough spot removal. 
During sorafenib treatment, instruct patients to avoid pressure points 
and items that rub, pinch, or create friction.  
• Instruct the patient to apply moisturizing lotions to their hands and fee t 
twice a day throughout treatment.  
7.4.7.2  PPE Treatment  
• Treatment may begin at the first clinical signs of PPE. At first 
occurrence, independent of grade, supportive measures should be 
promptly initiated.  
• Tender areas should be protected as follows:  
- Use socks/g loves to cover moisturizing creams  
- Wear well -padded footwear; use insole cushions or inserts.  
- Foot soaks with tepid water and Epson salts.  
• Creams may be used as follows:  
- Non-urea based creams may be applied liberally.  
- Keratolytic creams (eg, urea -based cre ams 10%, salicylic acid 6%) 
may be used on affected (hyperkeratotic) areas  3 times per day . 
- Alpha hydroxyl acids (AHA) -based creams may be applied liberally 
2 times a day. Approximately 5% to 8% provides gentle chemical 
exfoliation.  
- Topical analgesics (eg,  lidocaine 2%) may be used for pain control.  
- Topical corticosteroids like clobetasol 0.05% should be considered 
for patients with grade 2 or 3 PPE. Systemic steroids should be 
avoided.  
Use of Celecoxib  
A meta -analysis of PPE prevention  strategies conclude d that celecoxib, 
with statistically significant results, was the most promising agent (1). 
Therefore, celecoxib is recommended to reduce the sever ity of 
sorafenib -related PPE as follows:  
- Celecoxib 200 mg once daily should begin at the first clinical signs 
or symptoms of grade 2 PPE.  
Guidelines for sorafenib dosing modifications are listed in Section  7. 
MCC Protocol #:  MCC -14816   28 Version #: 1 2 
  Version Date: 04/22/2021 7.4.8  QT Prolongation Considerations   
7.4.8.1  ECGs will be ev aluated for QT c prolongation  prior to next scheduled 
treatment  
7.4.8.2  Any time QTc is evaluated during the course of the study:   
• When HR is between 60 -100 bpm, no manual read of QT required  
• When HR <  60 or >  100 bpm, manual read of QT by cardiologist is 
required, using Fridericia  correction  
Any questions or concerns about E CG readings will be reviewed with a 
cardiologist.  
7.4.8.3  To the extent possible, concurrent use of drugs known to cause 
clinically significant QT prolongat ion should be avoided.  Such drugs 
may be identified at the Credible Meds website 
(http://crediblemeds.org/login ). The Credible Meds  website requires free 
user registration to view the list of clinically relevan t QT prolonging 
drugs, eg, those known to carry a risk of causing Torsade s de Pointes  
(TdP) . QT prolonging drugs to be avoided during this trial are shown in 
the Credible Meds list of “drugs with known TdP risk.”   
7.4.8.4  When concurrent use of sorafenib  and any d rug on the Credible Meds 
list of “drugs with known TdP risk” cannot be avoided, review QTc prior 
to concurrent use . If pre -concuurent use QTc is:  
• grade 0 (<  450 ms), follow -up QTc evaluation should be done at the 
next scheduled follow -up visit.  
• grade 1 ( 4 50-480 ms), follow -up QTc ev aluation should be done 
within 8  days after concurrent use starts . 
• grade 2 (481 -500 ms), withhold sorafenib  until follow -up ECG at 
next possible opportunit y shows QTc grade 1 or less (≤ 480 ms); 
evaluate QTc within 8  days after reintroduction  of sorafenib . 
7.4.8.5  Any new onset of dysrhythmia on E CG during study treatment phase will 
be reviewed and managed with input from cardiology.  
7.4.8.6  For any episode of syncope (grade 3) or near syncope (pre -syncope 
grade 2)  or QTc grade 3 or greater (> 5 00 ms on 2 ECGs ), see  Section  
7.1.1 . 
7.5 Laboratory Monitoring and Clinical Exam  
Patient s in the safety lead -in cohort (for qualifying toxicity assessment) wil l be seen weekly 
for the first 4 weeks of combination st udy therapy , then every 2 weeks for the next 4 
weeks, and then monthly . Visits for subsequently enrolled patient s are required every 2 
weeks  for the first 8 weeks , then monthly . Assessments to be done at each visit are as 
shown in the Study Calendar . Serum valproic acid levels will be monitored every 2 weeks, 
or more frequently as clinically indicated  through the end of cycle 2. After cycle 2 they will 
be checked as clinically indicated . Determination of steroid dose will be  made at least 
MCC Protocol #:  MCC -14816   29 Version #: 1 2 
  Version Date: 04/22/2021 every 2 weeks (weekly in the safety lead -in cohort) and steroid  dose may be tapered at  the 
treating physician’s discretion if the patient demonstrates a stable to improved neurologic 
exam.  
In the event that a patient complains of abdominal p ain, serum amylase and lipase will also 
be checked. Severe abdominal pain warrants a CT scan of the abdomen to rule out 
visceral perforation  and pancreatitis .  
7.6 Duration of Therapy  
A cycle is defined as 4 weeks.  Treatment will continue for the duration of r esponse or 
stable disease.  
Study treatment continues until one of the following:  
• Investigator determination that discontinuation is in a patient’s best medical 
interest  
• Progression  
• Withdrawal of support of study sponsor  
The reason for study treatment disc ontinuation  and the date treatment  was discontinued  
must be documented in the OnCore CRF.  
7.7 Monitoring Patient  Compliance  
A drug diary will be provided to each patient  to use to track study drug administration. The 
diary will be reviewed by th e study team periodically (see Study C alendar ). Patient  reports 
of self -administration, review of medication diary and pill counts will be used to assess 
study medication compliance. Concurrent medication assessments will be used to captu re 
corticosteroid use and supportive care medications.  
7.8 Duration of Follow  Up 
Patients who discontinue treatment for any reason other than death  or their choice to 
withdraw  from all study follow -up remain on study in follow -up status for a n initial  30-
day AE evaluation period following the last dose of study agent(s). This 30 -day post -
treatment follow -up period is meant to capture resolution or stabilization of ongoing 
treatment -related AEs or evolution of new tre atment -related AEs.   
The initial AE follow -up period  may be extended if new or worsening treatment -related AEs 
require longer observation. Similarly, t he initial AE follow -up period may end early in the 
event of death, patient request to withdraw from follow -up, or initiation of new anti -cancer 
thera py. 
After the initial AE follow -up period, patients who are not evaluable for objective response 
(see Section 10.1) are off study. Patients who are evaluable for objective response enter 
an extended follow -up pe riod for progression and/or surv ival outcomes.  
Patients who discontinue treatment with an ongoing response ( PR or CR ) or with ongoing 
stable disease  (SD) are followed until the first evidence of progression after coming off 
treatment or until other anti -cancer therapy is initiated. At the onset of progression or 
MCC Protocol #:  MCC -14816   30 Version #: 1 2 
  Version Date: 04/22/2021 initiation of new therapy, whether this occurs during the initial or extended follow -up period, 
patients are followed only for survival.  
The primary reasons for a patient ’s discontinuation from stud y treatment and from follow -
up status are to be recorded in the source documents and the CRFs.  
Certain late -occurring AEs may be subject to reporting during the extended follow -up 
period (eg, secondary malignancies).  
8 ADVERSE EVENTS : DEFINITIONS AND REPO RTING 
REQUIREMENTS  
8.1 Definitions  
8.1.1  Adverse Event (AE)  
AE means any untoward medical occurrence associated with the use of a drug in 
humans,  whether or not considered drug related.  
8.1.2  Serious Adverse Event (SAE)  
An AE is considered “serious” if in the view of the inv estigator, it results in any of the 
following outcomes:  
• death, 
• a life -threatening AE  (An AE is consider “life -threatening” if, in the view of either 
the investigator or sponsor, its occurrence places the patient or subject at 
immediate risk of death. It do es not include an AE that,  had it occurred in a more 
severe form, might have caused death. ), 
• inpatient hospitalization or prolongation of existing hospitalization , 
• a persistent or significant disability/incapacity or substantial disruption of the 
ability t o conduct normal life functions, or  
• a congenital anomaly/birth defect.  
Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment; they may require medical or surgical intervention to prevent one of the 
outcomes  listed in this defin ition.  
8.1.3  Unanticipated Problem (UP)  
UPs include any incident, experience, or outcome that meets all of the following 
criteria:  
• unexpected (in terms of nature, severi ty, frequency) given (a) the research 
procedures that are described in the protocol -related documents; such as the 
IRB-approved research protocol and informed consent document; and (b) the 
characteristics of the subject population being studied;  
MCC Protocol #:  MCC -14816   31 Version #: 1 2 
  Version Date: 04/22/2021 • related or  possibly related to participation in the research (ie, there is a 
reasonable possibility that the incident, experience, or outcome may have been 
caused by the procedures involved in the research; and  
• suggests that the research places subjects or others at  a greater risk of harm 
(including physical, psychological, economic, or social harm) than was 
previously known or recognized.  
8.2 Adverse Event Characteristics  
8.2.1  CTCAE t erm (AE description) and grade:  The descriptions and grading scales 
found in the revised NCI  CTCAE version 4 .0 will be utilized for AE reporting. All 
appropriate treatment areas should have access to a copy of the CTCAE version 
4.0. A copy of the CTCAE version 4  can be downloaded from the CTEP website : 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm .  
8.2.2  Expectedness : AEs can be ‘Unexpected’ or ‘Expected’ . 
Unexpected  AEs are those AEs occurring in one or more subjects participating in  
the research protocol, the nature, severity, or frequency of which is not consistent 
with either:  
• The known or foreseeable risk of AEs associated with the procedures involved 
in the research that are described in (a) the protocol -related document, such as  
the IRB -approved research protocol, any applicable investigator brochure, and 
the current IRB -approved informed consent document, and (b) other relevant 
sources of information, such as product labeling and package inserts;  
or 
• The expected natural progress ion of any underlying disease, disorder, or 
condition of the subject(s) experiencing the AE and the subject’s predisposing 
risk factor profile for the AE.  
See Sections 9.1.9  (sorafenib), 9.2.8  (valproic acid), and 9.3.10  (sildenafil).  
8.2.3  Attribution  of the AE:  
• Definite – The AE is clearly related  to the study treatment.  
• Probable – The AE is likely related to the study treatment . 
• Possible – The AE may be related  to the study treatment.  
• Unlikely – The AE is doubtfully related to the study treatment.  
• Unrelated – The AE is clearly NOT related  to the study treatment.  
MCC Protocol #:  MCC -14816   32 Version #: 1 2 
  Version Date: 04/22/2021 8.3 Known A E List  
Expected AEs are those AEs, the specificity and seve rity of which is consistent with the 
listings for valproic acid, sorafenib or sildenafil  in Section 9 or those documented in the 
informed consent document . 
8.4 Time Period and Grade of A E Capture  
All AEs , regardless  of grade , will be recorded from the beginning of the study procedures 
through 30 days following the end of the study treatment.  
8.5 Procedures for Recording AEs , SAEs, Qualifying Toxicities, and UPs  
All AEs , SAEs, qualifying toxicities, and UPs  will be record ed in MCC’s On Core database 
program.  
In certain instances, it may be acceptable to record in OnCore only the highest grade of a 
toxicity occurring during a particular study segment when an event has serial fluctuations in 
grade over time.  
SAE’s will be ent ered into the OnCore SAE domain. UPs will be entered into the OnCore 
Deviations domain. An SAE that is both an SAE and a UP will be entered in both domains. 
For all SAEs, a corresponding entry should be made in the routine AE record to match the 
event entr ies in the SAE domain.
MCC Protocol #:  MCC -14816   33 Version #: 1 2 
  Version Date: 04/22/2021 8.6 Expedited Reporting Procedures  for SAEs , UPs, and Qualifying Toxicities  
Table 5. Expedited Reporting Requirements (Events, Report Recipients, and Time Frames)  
SAEs  UPs  
 Qualifying Toxicities1 
Principal Inve stigator , Co-
Investigator  (as listed 
below) , and Coordinating 
Study Team2, 3  Principal Investigator , Co-
Investigator  (as listed below) , 
and Coordinating Study 
Team2, 3 
 Principal Investigator , Co-
Investigator  (as listed 
below) , and Coordinating 
Study Team2 
 DSM C4 DSM C4 
 IRB5  
1 See Section  6.4.2 . 
2 Report event within 1 business day  of becoming aware of the occurrence.   
3 A de-identified PDF of an OnCore SAE or deviation record may be used for expedited 
repor ting purposes.  
4 Report event within 2 business days of becoming aware of the occurrence.  A de-identified 
PDF of an OnCore SAE or deviation record may be used for expedited reporting purposes.  
5 Each UP must be reported to the VCU IRB within 5 business day s of becoming aware of 
the occurrence.  
Principal Investigator:  
Mark Malkin, MD  
 
  
 
 
 
Coordinating Study Team : 
 
 Massey Cancer Center DSM C: 
 
9 PHARMACEUTICAL  INFORMATION  
  
 
 
  
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   34 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
   
 
 
   
 
  
 
 
   
 
 
  
 
 
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   35 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   36 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   37 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   38 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
   
 
 
 
   
 
 
  
  
  
 
  
  
 
       
       
       
        
       
       
        
        
       
       
       
       
        
        
        
       
       
        
        
        
        
        
       
       
       
       
       
        
       
       
        
        
        
       
       
        
        
 
 
 

MCC Protocol #:  MCC -14816   39 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   40 Version #: 1 2 
  Version Date: 04/22/2021  
  
 
 
 
    
   
 
 
  
  
  
 
  
      
      
      
      
      
      
      
  
      
      
      
  
      
  
      
  
      
      
  
 
      
  
      
      
  
      
      
  
      
      
      
      
      
      
      
  
      
 
 
 
 
 

MCC Protocol #:  MCC -14816   41 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   42 Version #: 1 2 
  Version Date: 04/22/2021    
 
 
  
 
 
 
 
 
 
 
 
 
 
   
 
 
   
 
 
 
 
  
  
 
 
 
 
  
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   43 Version #: 1 2 
  Version Date: 04/22/2021   
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   44 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   45 Version #: 1 2 
  Version Date: 04/22/2021   
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   46 Version #: 1 2 
  Version Date: 04/22/2021  
 
  
  
 
 
     
     
     
 
     
     
     
     
     
     
     
 
     
     
     
     
     
     
     
     
     
     
 
     
     
     
     
 
     
     
 
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   47 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
   
   
 
   
       
   
       
       
       
       
       
       
 
   
       
       
   
        
        
   
       
       
       
       
       
       
       
       
   
       
       
       
   
       
   
     
   
       
 
 

MCC Protocol #:  MCC -14816   48 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   49 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
  
 
 
  
 
 
 

MCC Protocol #:  MCC -14816   50 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
 
 
 
 
  
 
  
 
   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   51 Version #: 1 2 
  Version Date: 04/22/2021   
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 

MCC Protocol #:  MCC -14816   52 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 

MCC Protocol #:  MCC -14816   53 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
 
 
 
  
  
  
  
 
     
     
     
     
      
     
      
     
     
     
 
 
 
 
 
                          
          
          
          
         
          
          
          
           
 
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   54 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MCC Protocol #:  MCC -14816   55 Version #: 1 2 
  Version Date: 04/22/2021  
 
 
 
 
 
  
 
 
 
. 
10 MEASUREMENT OF EFFEC T 
10.1 Definitions  
Evaluable for toxicity.  All patient s will be evaluable for toxicity from the t ime of t heir first 
treatment with sorafe nib and/or valproic acid and/or sildenafil . 
Evaluable for qualifying toxicities for the safety lead -in. Only those patient s who have 
completed the first cycle  of therapy  (or have experienced a qualifying toxicity prior to the 
end of the first cycle ) will be evaluable for the safety lead -in. Qualifying toxicities will be 
defined in the  first cycle  only. Patient s must  have completed twice -daily sorafenib dosing 
for at least 21 out of the first 28 days  to be considered t o have had sufficient exposure to 
the regimen for qualifying toxicity evaluation . Patient s who are not evaluable for the 
qualifying toxicity assessment for the safety lead -in will be replaced.   
Evaluable for qualifying toxicities for the early stopping rul e after the safety lead -in. 
Patient s who have  initiated the first cycle of therapy will be considered evalu able for the 
early stopping rule. Qualifying toxicities will be defined in the  first cycle only. Patients who 
are not evaluable for the qualifying to xicity assessment for the early stopping rule will not 
be replaced  unless they were included in the safety -lead in . 
Evaluable for objective response.  Patient s who have  been treated with the combination 
of twice -daily sorafenib and valproic acid for a minim um of 28 days , and have had their 
disease re -evaluated , will be considered evalu able for response. These patient s will have 
their response classified according to the definitio ns stated below . Patient s who do not 
complete study dosing for at least 28 days , or those who do not have their disease re -
evaluated following initiation  of the combination of sorafenib and valproic acid, will be 
replaced to ensure that a sufficient number of patient s will be available for response  
evaluation.  
 
 

MCC Protocol #:  MCC -14816   56 Version #: 1 2 
  Version Date: 04/22/2021 10.2 Response Criteria  
The neurologic examination and the MRI or contrast -enhanced CT at each evaluation will 
be scored as follows:  
10.2.1  Neurologic Exam Status  
10.2.2  MRI Assessment: Based on Response Assessment in Neuro -Oncology working 
group (RANO) criteria (37). 
Table 13. RANO Criteria  
Response  Criteria  
Complete 
Respo nse 
 Requires all of the following:  Complete disappearance of all enhancing 
measurable and non -measurable disease sustained for at least 4 weeks; no new 
lesions; stable or improved non -enhancing (T2/FLAIR) lesions; and with patient 
off corticosteroids or o nly on physiological replacement doses.  Requires repeat 
MRI in 4 weeks for confirmation.  
Partial 
Response  Requires all of the following:  ≥ 50% decrease, compared with baseline, in the 
sum of products of perpendicular diameters of all measurable enhancing lesions 
sustained for at least 4 weeks; no progression of non -measurable disease; no 
new lesions; stable or improved non -enhancing (T2/FLA IR) lesions on the same 
or lower dose of corticosteroids compared to baseline scan;  and with patient on a 
dose corticosteroids not greater the dose at the time of baseline scan, and is 
stable or doing better clinically.  Requires repeat MRI in 4 weeks for c onfirmation.  
Stable 
Disease  Stable disease occurs if the patient does not qualify for complete response, 
partial response, or progression, and requires the following: Stable non -
enhancing (T2/FLAIR) lesions on the same or lower dose of corticosteroids 
compared with baseline scan and clinically stable status.  
 
In the event that the corticosteroid dose was increased for new symptoms and 
signs without confirmation of disease progression on neuroimaging, and 
subsequent follow -up imaging shows that this increas e in corticosteroids was 
required because of disease progression, the last scan considered to show stable 
disease will be the scan obtained when the corticosteroid dose was equivalent to 
the baseline dose.  
Progressive 
Disease  Progression is defined as any  of the following:  ≥ 25% increase in the sum of the 
products of perpendicular diameters of enhancing lesions, on stable or increasing 
doses of steroids; a significant increase in non -enhancing (T2/FLAIR) on stable 
or increasing dose of steroids compared wi th baseline scan or best response 
after initiation of therapy; the appearance of new lesions; clear progression of 
non-measurable lesions; definite clinical det erioration not attributable to other 
causes apart from tumor or to decreases in corticosteroid d ose. Table 12. Neurologic Exam Status as Compared to Pre -Treatment E xam 
Status  Criteria  
Better  No new neuro logic deficits. Must be on stable or decreasing dose of steroids, 
with stable to improved ECOG performance status  
Worse  New neurologic deficits, declining ECOG performance status, or requiring 
increasing dose of steroids to remain stable  
MCC Protocol #:  MCC -14816   57 Version #: 1 2 
  Version Date: 04/22/2021 10.2.3  Contrast -enhanced CT Assessment: Based on Macdonald Criteria  (38).  
Table 14. Macdonald Criteria    
Response  Criteria  
Complete 
Response  Requires all of the following: complete disappearance of all enhancing measurab le 
and non -measurable disease sustained for at least 4 weeks; no new lesions; no 
corticosteroids; and stable or improved clinically .  
Partial 
Response  Requires all of the following: ≥ 50% decrease compared with baseline in the sum of 
products of perpendicular diameters of all measurable enhancing lesions sustained 
for at least 4 weeks; no new lesions; stable or reduced corticosteroid dose; and 
stable or improved clinically .  
Stable 
Disease  Requires all of the following: does not qualify for complete response, partial 
response, or progression; and stable clinically . 
Progression  Defined by any of the following: ≥ 25% increase in sum of the products of 
perpendicular diameters of enhancing lesions; any new lesion; or clinical 
deterioration .  
*Table from (37) 
10.3 Considerations for Patients with Multifocal Disease  
For pat ients with multifocal disease, progressive disease is defined as ≥  25% increase in 
the sum of the products of perpendicular diameters of enhancing lesions compared with 
the smallest tumor measurements after the initiation of therapy.  The appearance of a ne w 
lesion or unequivocal, progression of non -target lesions will also be considered 
progression.   
Partial response is defined as a ≥  50% decrease, compared with baseline, in the sum of 
products of perpendicular diameters of all measurable enhancing lesions sustained for at 
least 4 weeks, with stable or decreasing corticosteroid dose  and with stable neuro logic 
exam . 
10.4 Timing of Imaging Studies  
For the purposes of this study, patients will be re -evaluated for response every 8 weeks. In 
addition to a baseline sca n, confirmatory scans should also be obtained 4 weeks following 
initial documentation of objective response  (PR or CR) .  
Evaluation of neurologic imaging can be confounded by factors such as edema  and subtle 
variances in i maging parameters . In the event th at imaging meets objective  progression  
criteria , but the patient‘s clinical status is stable or improving, with a stable or decreasing 
steroid dose, and, in the opinion of the investigator, the aggregate patient assessment is 
not definitive for progression , study therapy can continue at investigator’s discretion with 
repeat imaging at time of next scheduled assessment . If subsequent imaging again meets 
objective  progression  criteria , regardless of clinical and/or steroid dosing status, then 
progression crit eria will have been met, and the date of progression will  be noted as the 
earliest imaging  date that was consistent with objective progression . 
If clinical conditions raise the concern for progressive disease in between regularly 
scheduled interval scans, repeat imaging may be performed at the treating physician’s 
discretion.  
MCC Protocol #:  MCC -14816   58 Version #: 1 2 
  Version Date: 04/22/2021 10.4.1  Duration of Response  
Duration of overall response : The duration of overall response is measured from the 
time measurement criteria are met for a complete response  or a partial response  
(whichever is first recorded) until the first date that recurrent or progressive disease 
is objectively documented (taking as reference for progressive disease the smallest 
measurements recorded since the treatment started).  
The duration of overall comple te response  is measured from the time measurement 
criteria are first met for complete response  until the first date that progressive 
disease is objectively documented.  
Duration of stable disease : Stable disease is measured from the start of the 
treatment u ntil the criteria for progression are met, taking as reference the smallest 
measurements recorded since the treatment started, including the baseline 
measurements.   
10.4.2  PFS 
PFS is defined as the duration of time from start of treatment to time of symptomatic 
and/or radiographic progression or death, whichever occurs first.  
11 CORRELATIVE STUDIES  
11.1 PDGF Rα Expression in Primary Tumor Samples  
Analysis will take place on archived tissue. Patients being considered for enrollment onto 
this study will have had primary therapy for their high-grade glioma , which includes 
resection, when possible, with a minimum o f a core needle biopsy of the tumor for patients 
with unresectable disease. Some patients will also have had a biopsy of recurrent disease. 
Other patients will have had progression from a lower grade glioma, and multiple biopsies 
will be available to choos e from. The preferred tumor specimen is from the primary 
resection specimen at the time of initial treatment for high-grade glioma . 
11.2 Timing of Sample Collection and Analysis  
In the initial PDGF Rα-unselected cohort, archived samples may be obtained and submitted 
for initial processing any time after study consent is obtained, preferably within the first few 
weeks of study therapy. Analysis/interpretation of these samples may be done without 
regard  to participant initiation of study treatment. Samples may be held for batch 
processing, staining, and analysis until such time as it is determined whether the study will 
proceed to enrollment of only patients known to have PDGFRα -positive tumors.  
If the study continues to enrollment of a PDGFRα -positive cohort, archived samples will 
need to be collected, processed, and scored as part of the screening process to determine 
eligibility.  
After the first interim analysis for 6 -month PFS:  
• If the study continue s with enrollment of PDGF Rα-unselected patient s only, tissue 
collection , processing,  and analysis may continue , with the understanding that samples 
may be processed and/or analyzed for PDGFRα status in a non -CLIA -certified setting. In 
MCC Protocol #:  MCC -14816   59 Version #: 1 2 
  Version Date: 04/22/2021 this case, samples wi ll be deparaffinized  in VCU Anatomic Pathology, immunostained in 
the VCU Massey Cancer Center Clinical and Translational Research Laboratory (VCU 
MCC CTRL) and scored in VCU Anatomic Pathology.   
• If the study continues with enrollment of PDGF Rα-selected patients (only those who 
have PDGF Rα-positive tumors), results of PDGFRα  immunostaining will need to be 
available PRIOR TO enrollment.  Immunostaining for the PDGFRα -positive cohort will be 
performed in a CLIA -certified setting. In this case, for consistency,  all previously 
collected samples from the PDGFRα -unselected patient cohort will also undergo staining 
and analysis in the CLIA -certified setting.  
11.3 Collection of Specimens  
A total of 5 unstained slides, each with specimen 4 -microns thick, should be obtained . All 
slides will have PHI removed before submission for correlative testing and will be labeled 
with:  
• Study Number  
• Subject ID#  
• Surgical pathology accession #   
VCU MCC CTRL and VCU Anatomic Pathology will maintain logs of samples handled for 
correlative testing keyed by those 3 identifiers.  
To obtain a biopsy specimen from VCU archives, contact VCU Anatomic Pathology 
 and reference surgical pathology 
specimen number and block number. Provide a copy o f protocol specifications for sample 
collection and signed informed consent . 
• For the PDGFRα -unselected cohort,  make arrangements for de -identified slides to 
be obtained and submitted to the VCU MCC CTRL  to be stored until a 
determination is made about wher e the slides will be processed and analyzed .  
• For the PDGFRα -selected cohort, make arrangements for de -identified slides to be 
obtained and submitted to the VCU Anatomic Pathology for pre -enrollment 
processing and analysis to determine PDGFRα -status  
VCU An atomic Pathology 
 
 
 
  
  
   
  
 
To obtain an archived biopsy specimen from outside hospital, request that a tissue block 
be sent to Anatomic Pathology  at the above address, Attention  and 

MCC Protocol #:  MCC -14816   60 Version #: 1 2 
  Version Date: 04/22/2021 notify  to expect the specimen for research testing. The study team should 
coordinate with  to transfer the prepared slides from outside tissue blocks to the 
VCU MCC CTRL.  
If the outsid e hospital does not transfer blocks of tissue, request delivery of 5 unstained 
slides, each with specimen 4 -microns thick, directly to the study team. Blank slides from an 
outside hospital do not need to be sent to pathology for preparation, and may be sub mitted 
directly to the VCU MCC CTRL for immunostaining.  
11.4 Handling of Specimens  
Five unstained slides, each with specimens 4 microns thick, will be submitted for 
immunostaining.  
11.5 Immunostaining of Specimens  
Immunostaining and analysis will be done in either the VCU MCC CTRL or in a CLIA -
certified setting, per Section 11.2.  
11.6 Interpretation of Correlative Study  
 
 
 
 
 
 
 
 
11.7 Other Potential Pharmacodynamic Markers  
The laboratory of  at MCC will analyze the samples for the pharmacodynamic 
marker studies.  

MCC Protocol #:  MCC -14816                                                  61 Version #: 1 2 
            Version Date: 04/22/2021 12 STUDY CALENDAR  
Table 15. Study Calendar  
Event  BaselineA On TreatmentB Follow UpC 
Cycle 1  Cycle 2  Cycle 
3+ Initial    
30-Day 
Period  Extended  
Period  D1 D8 D15 D22 D1 D8 D15 D22 D1 
Informed Consent XD            
Demographics, Height  XD            
History and Physical Exam 
including Performance Status,  
Dermatologic and Neurologic  
Assessments  X XE XF X XF X  X  X   
Vital Si gns, Weight  X X XF X XF X  X  X   
Baseline Symptoms  X            
Adverse Event Assessment   X XF X XF X  X  X XC  
Concurrent Medications, 
Including Steroid Dosing 
Review  X X XF X XF X  X  X   
Study Medication Diary Review 
and Pill  
Count   X XF X XF X  X  X   
Pregnancy Test, Counseling XG            
ECG X  XH      XH   
Tumor Imaging XI XJ 
Survival, Alternative Therapies            XC XK 
Archived Tumor Tissue XL            
CBC with Differential, Platelets X XB XF X XF X  X  X   
Basic Metabolic Panel ,M,N 
Hepatic Panel ,O Magnesium,N 
PhosphorusN X XB XF X XF X  X  X   
PT, INRP X X   
Serum Valproic Acid LevelQ X X   
Serum Ammonia  X    
Valproic Acid  Initiate, t itrate , and/or maintain  level ≥ LLN for the laboratory and dose per Sections 6 
and 9.   
Sorafenib   Initiate on C1D1, provided valproic acid level is ≥ LLN for the laboratory ; 
continue dosing per Sections 6 and 9.   
Sildenafil     
MCC Protocol #:  MCC -14816                                                  62 Version #: 1 2 
            Version Date: 04/22/2021 A. Within 2 weeks prior to enrollment  unless otherwise noted .  
B. C1D1 labs do not need to be repeated on C1D1 if done within 7 days prior to initiation of study treatment. Other C1D1 
assessments may  be performed within 3 days prior to day 1 dosing. In cycle 1, weekly assessments must  be done within +/ - 1 
day of required time  point. In cycle 3 and subsequent cycles, assessments must  be done within +/ - 3 days of scheduled time  
point; greater variations  in timing may be permitted after cycle 2, with prior principal investigator/designee notification . For 
patients who are still on study for longer than 36 months , assessments may be done every other cycle ( approximately every 8 
weeks).  
C. See Section 7.8: The 30 -day post -treatment follow -up period is meant to capture resolution or stabilization of ongoing 
treatment -related AEs or evolution of new treatment -related AEs.  
D. Within 4 weeks prior to initiation of study tr eatment . 
E. If baseline history and physical exam is performed on a day other than  C1D1 , a brief visit to determine neurologic stability on 
current dose of steroids is also required  on day 1 or day before .  
F. Only patient s in the safety lead-in cohort . 
G. For wome n capable of pregnancy: pregnancy test at baseline; subsequently, review pregnancy risks and offer pregnancy test  
H. First “on -treatment” E CG is done approximately C1D8 -C1D15  to evaluate acute changes relative to the study drug 
combination; the second is done  approximately C3D1 to evaluate changes after a more chronic dosing of study drug 
combination . 
I. MRI or contrast -enhanced CT within 3 weeks prior to enrollment. An MRI is the preferred modality in all patients without a 
contraindication to MRI. Baseline and follow -up scans must be performed using the same modality.  
J. Imaging to be done to assess response every 2 months from initiation of treatment until off -study due to patient withdrawal, 
progression , or death. If MRI or contrast -enhanced CT shows response the n repeat a fter 1 month to confirm  response and 
then follow every 2 months from time of confirmatory MR I or CT.  Patients with symptoms suggestive of progression  may have 
imaging done between  regularly scheduled scans, any time there is clinical concern for progressive disease . See also Section 
10.4. 
K. See Section 7.8: After stopping study treatment, capture initiation of new therapy, first new progression date, and/or sur vival 
status since last observation approximately every 2 months during extended follow -up.  
L. Obtain and analyze archived tumor tissue per Section 11. During enrollment of the initial PDGFRα -unselected subgroup ( prior 
to first interim analysis), archived tumor tissue must be obtained and analyzed, but analysis does not need to be performed 
prior to enrollment. After the first interim analysis, if the study proceeds to include only PDGFRα -positive patients, archive d 
specimen analysis for PDGFRα will be required, and results must be known, prior to enrollment.  
M. Sodium, potassium, carbonate, chloride, glucose, calcium, BUN, creatinine.  
N. Additional assessments may be done at investigator discretion in patients with conge stive heart failure, bradyarrhythmias, 
those on drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities.  
O. ALT, AST, ALP, total bilirubin, direct bilirubin, albumin, total protein.  
P. In patients taking warfarin: at baseline and then as clinically indicated.  
MCC Protocol #:  MCC -14816                                                  63 Version #: 1 2 
            Version Date: 04/22/2021 Q. Initial level approximately  5 days after starting valproic acid. Once on study treatment, check level at least every 2 weeks, or 
more frequently if clinically indicated , through the end of cycle 2. Af ter cycle 2, check only as clinically indicated.  
MCC Protocol #:  MCC -14816  64 Version #: 1 2 
  Version Date: 04/22/2021 13 STATISTICAL CONSIDER ATIONS  
13.1 Study Design  
This is a single -arm phase 2 study of sorafenib, valproic acid, and sildenafil in the 
treatment of pati ents with recurrent high-grade glioma . The primary objective i s to 
determine the efficacy of the  drug combination in terms of 6 -month PFS. This study will be 
conducted through an adaptive design po tentially  including  2 Simon’s two -stage mini -max 
designs. Initially , recurrent high-grade glioma  patients will be enrolle d, regardless of tumor 
molecular subtype, to determi ne the efficacy of the drug combination. If efficacy criteria are 
not met in patients inclusive of all molecular subtypes, then only patients with tumors that 
express PDGFRα will be enrolled. Therefore, 2  Simon’s designs may be included; the first 
is for patients in the entire cohort and the second is for patients with PDGFRα expressing 
tumors only if efficacy criteria  are not met  in the entire cohort. Details on the rational e of 
the adaptive  design can be  found in Section 1.9.  
The total expected sa mple size is estimated to be 44, with a range from 32 to 66 patients .  
Both a safety lead -in and a safety stopping rule are provided to monitor  whether there are 
“too many” unexpected toxicities related  to the drug combination, as patients continue 
being enrolled in the study. To ensure safety with respect to any interaction toxicity effects 
among the 3 drugs, we provide a safety lead -in rule for the first 6 qualifying  toxicity -
evaluable patient s—like a “3+3” phase 1 design. Once a dose has been identified wherein  
< 2 of 6 qualifying toxicity -evaluable patient s develop a qualifying toxicit y during the first 4 
weeks of therapy, then that dose will be used for expansion. Qualifying toxicities are 
defined in Section 6.4.2 .  
Once the dose for expansion to the full cohort is identifie d, then an early sequential safety 
stopping rule which is based on the occurrence rate of qualifyin g grade 3 or greater 
toxicities is provided to monitor safety for any toxicities in the expansion. The safet y lead-in 
rule is designed for  a “3+3” study and is used to enhance  safety analysis for the first 6 
qualifying toxicity -evaluable patient s on the st udy, whereas  the sequential stopping rule for 
subsequent enrollment has considered the variability of toxicity rate by  confidence intervals 
based on observed data and scenarios where unacceptable toxicity could occur prior to 
study suspension . More details  on the clinical rational e are in Section 1.7. Details on the 
safety lead -in and safety stopping rule are in Section 13.6. 
13.2 Sample Size/Accrual Rates  
The sample size a nd power are calculated based on Simon’s two -stage mini -max design 
which minimizes th e expected maximum sample size (35). The primary outcome, 6 -month 
PFS, is considered as a binary variabl e, ie, a patient either has 6 -month PFS or not. Per 
the previous studies of secon d-line therapy in GBM, we assume that the null hypothesis, 
the proportion of patients who have 6 -month PFS, is ≤ 20%, ie, p0  ≤ 0.2, which is 
unacceptably low, and the true proportion is p1=0.4 . With a one -sided type I error of 5% 
and power of at least 80%,  the first stage will enroll  16 response -evaluable patients. If 
there are 3 or less response -evaluable patients who have 6 -month PFS, then the trial in 
the unselected  patient population will end . If 4 or more response -evaluable patients have 
6-month PFS, t hen the trial will enroll an additional 17 response -evaluable patients into the 
second stage. If 11 or more out of the total of 33 response -evaluable patients have 6 -
MCC Protocol #:  MCC -14816  65 Version #: 1 2 
  Version Date: 04/22/2021 month PFS, the drug combination meets efficacy criteria and further studies can be 
pursued .  
As mentioned  in Section  13.1, the study will be conducted through an a daptive design 
possibly with 2  Simon’s two -stage designs. Both of these  Simon’s designs will share the 
same parameters/settings , assumptio ns for sample size , and power calculations. The total 
sample size may range from 32  to 66. We expect that it is very likely that the study will 
enroll 16 response -evaluable patients inclusive of  all molecular subtypes, and then a total 
of 16 response -evalu able patients with PDGFRα -expressing tumors in the first stage  
(inclusive of patients with PDGFRα -positive tumors in the first  interim analysis ), and an 
additional 17 response -evaluable patients with PDGFRα -expressi ng tumors  in the second 
stage. Per previous studies, PDGFRα is the third most common gene event identified in 
GBM, and about 30 -40% patients have positive PDGFRα expression among all GBM 
patients , with a higher percentage in patients with transformed GBM from lower grade 
glioma (39). Therefore, we expect that the total sample size for the adaptive design is 
about 44  response -evaluable patients . Based on  previous recruitmen t at the Massey 
Cancer Center, it is estimated that  8-12 patients  will be enrolled per year, and therefore, it 
is estimated that the study will complete  enrollment in approximately  4 years and be closed 
in approximately  5 years. It is likely that the accru al rate for the PDGFRα expression  cohort 
will be slower than for the entire population and the study team will invite more clinical sites 
to increase the accrual rate.   
13.3 General Statistical Analysis  
Patient demographics, AEs and SAEs, disease status,  treatment dosing level, treatment 
status, clinical response, time -to-event intervals etc. will be recorded  and summary 
descriptive statistics will be calculated. The clinical response rates will also be summarized 
using descriptive statistics for each cohort, a long with their corresponding 95% confidence 
intervals.  
13.4 Analysis of Primary Endpoints  
The primary endpoint is whether a patient has a 6 -month PFS or not. The proportion  of 
response -evaluable patients who have 6 -month PFS in the entire cohort and in PDGFRα 
expressing tumor and their confidence intervals will be calculated , respectively. The 
Kaplan -Meier method will be used to describe the time to progression and the median time 
to progression will be estimated, along with its 95% confidence intervals (40), for the entire 
population and for PDGFRα expression, respectively. Cox regression analysis will be used 
to evaluate baseline characteristics and any potential covariates.  
13.5 Analysi s of Secondary Endpoints  
The overall best response rate to the drug combination will be estimated for the entire 
study population and for the PDGFRα -expressing high-grade glioma  cohort, along with the 
95% confidence intervals.  
The Kaplan -Meier method will  be used to describe the time to overall survival and the 
median time to overall survival will be estimated, and along with its 95% confidence 
intervals, for the entire population and for PDGFRα expression, respectively. Cox 
regression analysis will be use d to evaluate baseline characteristics and any potential 
covariates.  
MCC Protocol #:  MCC -14816  66 Version #: 1 2 
  Version Date: 04/22/2021 13.6 Safety Lead -in, and Safety Stopping Rule  
13.6.1  Safety Lead -in 
The first 6 patient s will be treated as a single dose -level safety lead -in prior to 
continuation of accrual of the entire study cohort. The lead -in rule is designed for a 
“3+3” study and is used to enha nce safety analysis for the first 6 patient s on the 
study, wherein the sequential stopping rule has considered the variability of toxicity 
rate by  confidence intervals based on observed  data and scenarios where 
unacceptable toxicity could occur prior to study suspension . Patient s will be 
evaluated for qualifying toxicities  as defined in Section 6.4.2 . If < 2 of 6 qualifying 
toxicity -evaluable patient s complete the first 4 weeks  of therapy wit hout a qualifying 
toxicity , then the dose is considered safe for expansion to the remainder of the 
entire study cohort.  If ≥ 2 of 6 qualifying toxicity -evaluable patient s experience a 
qualifying toxicity  during the first 4 weeks  of therapy, doses will be modified and an 
additional 6 patient s enrolled for qualifying toxicity  evaluation. In this case, the 
protocol will be placed on hold until the protocol is amended to specify the modified 
doses. Once a dose h as been identified wherein < 2 of 6 patient s develop  a 
qualifying toxicity  during the first 4 weeks  of therapy, then that dose will be  used for 
enrollment of the entire study cohort . In the event  that toxicity develops late, the 
stopping rule below will re main in effect to trigger review by the DSM C.  
13.6.2  Sequential Safety Stopping Rule  after the Safety Lead -in 
In addition to the safety lead-in described above , a formal sequential stopping 
guideline , which is based on the occurrence rate of qualifying toxicitie s, is designed  
for a phase 2 study, with a relatively looser threshold than the safety lead -in rule . If 
the stopping guideline is reached, accrual is stopped and a thorough review of the 
safety data is completed by the DSM C. The stopping guideline indicate s a level of 
concern based on the occurrence rate  of qualifying toxicities . However, the  stopping 
guideline is not an indicator  that an insurmountable  safety problem exist s. Likewise, 
the fact that a stopping guideline is not reached does not provide assur ance that the 
drug combination is safe.  Qualifying toxicity is defined in Section 6.4.2 . 
Previous studies of sorafenib have shown t he acceptable occurrence rate for grade 
3 or greater  toxicities is ≤ 35% (41). Using a binomial probability calculation, values 
of “m” (number of patients with qualifying toxicities ) and "n"  (number of qualifying 
toxicity -evaluable patients that have been treated)  are selected s uch that  the two -
sided 95% confidence interval of the sequential observed occurrence toxicity rate 
keeps containing the prefixed acceptable occurrence rate ≤ 35%. 
More specifically, the following values of  m/n apply  to those patients who are 
qualifying tox icity evaluable : 5/7, 6/8-9, 7/10-11, 8/12-13, 9/14 -15, 10/16 -17, 11/18 -
19, 12/20 -21, 13/2 2-23, 14/2 4-25, 15/2 6-28, 16/29-30, 17/3 1-32, 18/3 3-34, 19/3 5-
37, 20/3 8-39, 21/4 0-41, 22/4 2-44, 23/45 -46, 24/47 -48, 25/49 -51, 26/52 -53, 27/54 -
56, 28/57 -58, 29/59 -61, 30/62 -63, 31/6 4-65, 32/66 . If, at any time,  m/n reache s the 
values shown, accrual to the study protocol is stopped and the accumulated safety 
data is submitted to the DSM C for evaluation. Please refer to Section 6.4.2  for a list 
of qualifying toxicities.  
MCC Protocol #:  MCC -14816  67 Version #: 1 2 
  Version Date: 04/22/2021 13.6.3  Summary of Safety Monitoring Plan  
As mentioned in Section 13.6.1 , once a dose has been identified wherein  < 2 of 6 
patient s develop a qualifying toxicity  during the fi rst 4 weeks of therapy, then the 
study will be conducted through a Simon’s two -stage design ( Section 13.1) at that 
dose for the entire population first and then for the PDGFRα -expressi ng population. 
As mentioned  in Sections 13.1-13.2, 16 patient s will be enrolled for the first stage for 
the entire po pulation. The monitoring plan for  the 16 patient s is summariz ed in the 
table  below. Subsequent  patient s will be  monitored as described in Section 13.6.2 .  
Table 16. Summary of Safety Monitoring Plan  
Number of 
qualifying toxicity -
evaluable patient s Cumulative saf ety monitoring plan  
The first 6 patient s  Must have <  2/6 qualifying toxicity -evaluable patients  as 
indicated by the safety lead -in rule in Section 13.6.1  
The next  6 patient s  Of the 7 -12 qualifying toxicity -evaluable patient s, must have 
< 5-8 patient s who develop qualifying toxicities , as indicated 
in the sequential safety stopping rule in Section 13.6.2  
The next 4 patient s  Of the 13 -16 qualifying toxicity -evaluab le patient s, must 
have < 8 -10 patient s who develop qualifying toxicities, as 
indicated in the sequential safety stopping rule in Section 
13.6.2  
Further  patient s  Continue monitoring of qualifying toxicity -evalu able patients 
as in Section 13.6.2   
13.7 Evaluability for  Qualifying Toxicity , Toxicity, Response  
Each registered patient will be deemed as  evaluable for toxicity, qualifying toxicities and 
response as per Section 10.1: 
For response evaluability, the patients are coded as having a response or not . 
• Responders - Best response assessment is complete response  or partial response  
• Non-Responders - Best response assessment is  stable disease or progressive 
disease  or those patients who were not assessed or not evaluable   
• The coding of patient s as responders or non -responders will be made  by the study 
team  with the concurrence of the biostatistician.  
14 DATA AND SAFETY MONI TORING PLAN  (DSMP ) 
14.1 Study Team  
The study team, consisting of physicians, research nurses, clinical research associates, 
study statistician, and regulatory personnel, will have primary responsibility for study 
conduct. The study team will maintain a study summary and m eet a t least monthly  while 
patients are on study treatment. The study statistician will meet with the study team at least 
quarterly. Meetings will include, but not be limited to, reportable  AEs and UPs , and an 
update of the ongoing study summary that descr ibes study progress in terms of the study 
MCC Protocol #:  MCC -14816  68 Version #: 1 2 
  Version Date: 04/22/2021 schema. The appropriateness of further  patient  enrollment and the specific intervention for 
a next patient  enrollment are addressed. All meetings including attendance  are 
documented . 
14.2 Monitoring and Auditing  
14.2.1  MCC Com pliance Office  
Compliance specialists  in the MCC Compliance Office will provide  ongoing  
monitoring and auditing for this trial .  
14.2.2  Data and Safety Monitoring Committee  
The study will be reviewed by the MCC Data and Safety Monitoring Committee 
(DSMC) initiall y according to the risk level specified by the MCC Protocol Review 
and Monitoring Committee (PRMC) and then according to a schedule based on 
study status and quality indicators. The DSMC reviews reports of the sponsor -
investigator/study team and the MCC Co mpliance Office focusing on data integrity 
and patient safety.  
15 REGULATORY COMPLIANC E AND ETHICS  
15.1 Ethical Standard  
This study will be conducted in conformance with the principles set forth in The Belmont 
Report: Ethical Principles and Guidelines for the Prot ection of Human Subjects of 
Research  (US National Commission for the Protection of Human Subjects of Biomedical 
and Behavioral Research, April 18, 1979).  
15.2 Regulatory Compliance  
This study will be conducted in compliance with the protocol  and applicable regu latory 
requirements.  
15.3 Informed Consent Process  
Informed consent is a process that is initiated prior to the individual’s agreeing to 
participate in the study and continues throughout the individual’s study participation. 
Extensive discussion of risks and po ssible benefits of this therapy will be provided to the 
patient s and their families. Consent forms describing in detail the study 
interventions/ products, study procedures, and risks are given to the patient  and written 
documentation of informed consent is required prior to starting intervention/administering 
study product. Consent forms will be IRB -approved and the patien t will be asked to read 
and review the document. Upon reviewing the document, the investigator will explain the 
research study to the patient and answer any questions that may arise. The patien t will 
sign the informed consent document prior to any procedures being done specifically for the 
study. The patient s should have the opportunity to discuss the study with their surrogates 
or think abo ut it prior to agreeing to participate. The patient s may withdraw consent at any 
time throughout the course of the trial. A copy of the informed consent document will be 
given to the patient s for their records. The rights and welfare of the patient s will b e 
protected by emphasizing to them that the quality of their medical care will not be 
adversely affected if they decline to participate in this study.  
MCC Protocol #:  MCC -14816  69 Version #: 1 2 
  Version Date: 04/22/2021 15.4 Patient  Confidentiality  
Patient  confidentiality is strictly held in trust by the participating investigat ors, their staff, 
and the sponsor(s) and their agents. This confidentiality is extended to cover testing of 
biologic samples and genetic tests in addition to the clinical information relating to 
participating patient s. 
The study protocol, documentation, da ta, and all other information generated will be held in 
strict confidence. No information concerning the study or the data will be released to any 
unauthorized third party without prior written approval of the sponsor -investigator . 
The study monitor or oth er authorized representatives of the sponsor may inspect all 
documents and records required to be maintained by the investigator, including but not 
limited to, medical records (office, clinic, or hospital) and pharmacy records for the patien ts 
in this stud y. The clinical study site will permit access to such records.  
16 DATA  COLLECTION AND MANAGE MENT  
16.1 CRFs and Data Collection  
Data Massey Cancer Center On Core data management will provide standard CRFs and 
create study -specific CRFs to be able to capture all info rmation requ ired by the protocol. 
The CRFs will be approved by the study team to ensure the most effective data 
acquisition.  
The investigator(s) and study coordinator(s) must maintain source documents for each 
patient  in the study. All information on CRFs  will be traceable to these source documents,  
which are generally maintained in the patient ’s file.  
All CRFs should be completed and available for collection within a timely manner,  
preferably no more than 14 days after the patient ’s visi t. 
16.2 Study Record Re tention  
The investigator will maintain all study records according to applicable regulatory 
requirement(s).   
MCC Protocol #:  MCC -14816  70 Version #: 1 2 
  Version Date: 04/22/2021 17 REFERENCES  
1. Macedo LT, Lima JP, dos Santos LV, Sasse AD. Prevention strategies for chemotherapy -
induced hand -foot syndrome: a  systematic review and meta -analysis of prospective 
randomised trials. Support Care Cancer . 2014; 22:1585 -1593.  
2. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed 
in the United  States in 2004 –2005. Hinsdale, IL: CBTRUS;  2009. Available at 
http://www.cbtrus.org/reports/2009 -NPCR -04-05/CBTRUS -NPCR2004 -2005 -Report -.pdf. 
3. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAng elis LM, Robins HI, 
Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape 
KD, Hibberts J, Peterson PM, Prados MD, North American Brain Tumor C. Progression -free 
survival: an important end point in evaluating therapy for rec urrent high -grade gliomas. 
Neuro Oncol . 2008; 10:162 -170. PMCID: PMC2613818.  
4. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK. 
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinica l 
trials. J Clin Oncol . 1999; 17:2572 -2578.  
5. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med . 2008; 359:492 -507. 
6. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos 
N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab 
alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol . 2009; 
27:4733 -4740.  
7. Park MA, Reinehr R, Haussinger D, Voelkel -Johnson C, Ogretmen B, Yacoub A, Grant S, 
Dent P. Sorafenib activa tes CD95 and promotes autophagy and cell death via Src family 
kinases in gastrointestinal tumor cells. Mol Cancer Ther . 2010; 9:2220 -2231. PMCID: 
PMC2933415.  
8. Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Haussinger D, Reinehr R, Larner A, 
Spiegel S, Fisher PB, Voelkel -Johnson C, Ogretmen B, Grant S, Dent P. Vorinostat and 
sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+) -de novo 
ceramide -PP2A -reactive oxygen species -dependent signaling pathway. Cancer Res . 2010; 
70:6313 -6324. PMCID: PMC2918282.  
9. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori 
F, Martinelli G, Fiorentini C, Cipolla CM. Prognostic value of troponin I in cardiac risk 
stratification of cancer patients undergoing  high-dose chemotherapy. Circulation . 2004; 
109:2749 -2754.  
10. Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf 
M, Lee R, Roberts JD, Fisher PB, Grant S, Dent P. Vorinostat and sorafenib synergistically 
kill tumor cell s via FLIP suppression and CD95 activation. Clin Cancer Res . 2008; 14:5385 -
5399. PMCID: PMC2561272.  
11. Duenas -Gonzalez A, Candelaria M, Perez -Plascencia C, Perez -Cardenas E, de la Cruz -
Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: prec linical, clinical and 
transcriptional effects on solid tumors. Cancer Treat Rev . 2008; 34:206 -222. 
12. Venugopal B, Evans TR. Developing histone deacetylase inhibitors as anti -cancer 
therapeutics. Curr Med Chem . 2011; 18:1658 -1671.  
13. Reikvam H, Ersvaer E , Bruserud O. Heat shock protein 90 - a potential target in the 
treatment of human acute myelogenous leukemia. Curr Cancer Drug Targets . 2009; 9:761 -
776. 
14. Tang Y, Yacoub A, Hamad H, Poklepovic A, Tye G, Grant S, Dent P. Sorafenib and HDAC 
inhibitors syn ergize to kill CNS tumor cells. Submitted for Publication . 2012.  
MCC Protocol #:  MCC -14816  71 Version #: 1 2 
  Version Date: 04/22/2021 15. Black KL, Yin D, Ong JM, Hu J, Konda BM, Wang X, Ko MK, Bayan JA, Sacapano MR, 
Espinoza A, Irvin DK, Shu Y. PDE5 inhibitors enhance tumor permeability and efficacy of 
chemotherapy in a ra t brain tumor model. Brain Res . 2008; 1230:290 -302. PMCID: 
PMC2632551.  
16. Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng X, Abraham I, 
Ambudkar SV, Talele TT, Fu LW, Chen ZS. Sildenafil reverses ABCB1 - and ABCG2 -
mediated chemotherap eutic drug resistance. Cancer Res . 2011; 71:3029 -3041. PMCID: 
PMC3078184.  
17. Agarwal S, Sane R, Ohlfest JR, Elmquist WF. The role of the breast cancer resistance 
protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther . 2011; 
336:223 -233. PMCID: PMC3014301.  
18. Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, 
Marcello J, Herndon JE, 2nd, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman 
HS. Effect of CYP3A -inducing anti -epileptics on sorafenib e xposure: results of a phase II 
study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J 
Neurooncol . 2011; 101:57 -66. PMCID: PMC3102498.  
19. Zustovich F, Landi L, Lombardi G, Porta C, Galli L, Fontana A, Amoroso D, Galli C, 
Andreu ccetti M, Falcone A, Zagonel V. Sorafenib plus daily low -dose temozolomide for 
relapsed glioblastoma: a phase II study. Anticancer Res . 2013; 33:3487 -3494.  
20. Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, 
Yung WK, Dr appatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, 
Cloughesy TF, Gilbert MR, Wen PY. Phase I/II study of sorafenib in combination with 
temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor 
Consortium study  05-02. Neuro Oncol . 2012; 14:1511 -1518. PMCID: PMC3499017.  
21. Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Phuphanich S, Nabors LB, 
Rosenfeld MR, Mikkelsen T, Grossman SA, New Approaches to Brain Tumor Therapy C. 
NABTT 0502: a phase II and  pharmacokinetic study of erlotinib and sorafenib for patients 
with progressive or recurrent glioblastoma multiforme. Neuro Oncol . 2013; 15:490 -496. 
PMCID: PMC3607264.  
22. Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, Kimlinger TK, Northf elt 
DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC. Phase II study of bevacizumab in 
combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer 
treatment group trial. Clin Cancer Res . 2013; 19:4816 -4823. PMCID: PMC3869574.  
23. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a 
direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol 
Chem . 2001; 276:36734 -36741.  
24. Gottlicher M, Minucci S, Zhu P, Kramer O H, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, 
Nervi C, Pelicci PG, Heinzel T. Valproic acid defines a novel class of HDAC inhibitors 
inducing differentiation of transformed cells. EMBO J . 2001; 20:6969 -6978. PMCID: 
PMC125788.  
25. Weller M, Gorlia T, Cair ncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, 
Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, 
Stupp R. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial 
for glioblastoma. Neur ology . 2011; 77:1156 -1164. PMCID: PMC3265044.  
26. Guthrie GD, Eljamel S. Impact of particular antiepileptic drugs on the survival of patients with 
glioblastoma multiforme. J Neurosurg . 2013; 118:859 -865. 
27. Barker CA, Bishop AJ, Chang M, Beal K, Chan TA. Valproic acid use during radiation 
therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys . 
2013; 86:504 -509. 
MCC Protocol #:  MCC -14816  72 Version #: 1 2 
  Version Date: 04/22/2021 28. Felix FHC, de Araujo OL, da Trindade KM, Trompieri NM, Fontenele JB. Survival of children 
with malignant brai n tumors receiving valproate: a retrospective study. Childs Nervous 
System . 2013; 29:195 -197. 
29. Kerkhof M, Dielemans JCM, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, 
Vecht CJ. Effect of valproic acid on seizure control and on survival in pati ents with 
glioblastoma multiforme. Neuro -Oncology . 2013; 15:961 -967. 
30. Rokes CA, Remke M, Guha -Thakurta N, Witt O, Korshunov A, Pfister S, Wolff JE. Sorafenib 
Plus Valproic Acid for Infant Spinal Glioblastoma. Journal of Pediatric Hematology 
Oncology . 2010; 32:511 -514. 
31. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with 
preserved ejection fraction: a target of phosphodiesterase -5 inhibition in a 1 -year study. 
Circulation . 2011; 124:164 -174. 
32. Gomberg -Maitland M, Mai tland ML, Barst RJ, Sugeng L, Coslet S, Perrino TJ, Bond L, 
Lacouture ME, Archer SL, Ratain MJ. A dosing/cross -development study of the multikinase 
inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther . 
2010; 87:303 -310. 
33. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner 
JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, 
Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J 
Med. 2005; 352:997 -1003.  
34. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, 
Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, 
Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, J ames CD, Sarkaria JN, Brennan 
C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, 
Hayes DN. Integrated genomic analysis identifies clinically relevant subtypes of 
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer 
Cell. 2010; 17:98 -110. PMCID: PMC2818769.  
35. Simon R. Optimal two -stage designs for phase II clinical trials. Control Clin Trials . 1989; 
10:1-10. 
36. Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A, Anderson S, Bukows ki R, 
Eisen T, Escudier B. Long -term safety of sorafenib in advanced renal cell carcinoma: follow -
up of patients from phase III TARGET. Eur J Cancer . 2010; 46:2432 -2440.  
37. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J,  
Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp 
R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response 
assessment criteria for high -grade gliomas: response assessment in neuro -oncology 
working group. J Clin Oncol . 2010; 28:1963 -1972.  
38. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II 
studies of supratentorial malignant glioma. J Clin Oncol . 1990; 8:1277 -1280.  
39. Cancer Genome Atlas Research N. Comprehensive gen omic characterization defines 
human glioblastoma genes and core pathways. Nature . 2008; 455:1061 -1068. PMCID: 
PMC2671642.  
40. Brookmeyer R, Crowley JJ. A confidence interval for the median survival time. Biometrics . 
1982; 38:29 -41. 
41. Nexavar USA Prescrib ing Information. Bayer HealthCare Pharmaceuticals Inc.; 2011.  
MCC Protocol #:  MCC -14816  73 Version #: 1 2 
  Version Date: 04/22/2021 APPENDIX 1 . PERFORMANCE STATUS  CRITERIA  
ECOG Performance Status Scale  Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
0 Normal activity. Fully active, able 
to carry on all pre-disease 
performance without restriction.  100 Normal, no complaints, no evidence 
of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of 
disease.  
1 Symptoms, but ambulatory.  
Restricted in physically strenuous 
activity, but ambul atory and able 
to carry out work of a light or 
sedentary nature (eg, light  
housework, office work).  80 Normal activity with effort; some 
signs or symptoms of disease.  
70 Cares for self, unable to carry on 
normal activity or to do active work.  
2 In bed < 50% of the time.  
Ambulatory and capable of all self -
care, but unable to carry out any 
work activities. Up and about more 
than 50% of waking hours.  60 Requires occasional assistance, but 
is able to care for most of his/her 
needs.  
50 Requires considera ble assistance 
and frequent medical care.  
3 In bed >50% of the time. Capable 
of only limited self -care, confined 
to bed or chair more than 50% of 
waking hours.  40 Disabled, requires special care and 
assistance.  
30 Severely disabled, hospitalization 
indicated.  Death not imminent.  
4 100% bedridden. Completely 
disabled. Cannot carry on any 
self-care. Totally confined to bed 
or chair.  20 Very sick, hospitalization indicated. 
Death not imminent.  
10 Moribund, fatal processes 
progressing rapidly.  
5 Dead.  0 Dead.  
 
MCC Protocol #:  MCC -14816  74 Version #: 1 2 
  Version Date: 04/22/2021 Appendix 2. Cockcroft -Gault Equation  
Calculated Creatinine Clearance (Cockcroft and Gault)  
 
Creatinine Clearance (mL/min) = {(140 - Age) ×  Wt in kg ×  
G} / (Creat ×  72) 
G = 1 (males); G=0.85 (females)  
 
MCC Protocol #:  MCC -14816  75 Version #: 1 2 
  Version Date: 04/22/2021 Appendix 3. NYHA Classification of Heart Failure  
Class  Description  
I No symptoms. Ordinary physical activity such as walking and climbing stairs does not 
cause fatigue or dyspnea.  
II Symptoms with ordinary physical activity. Walking or climbing stairs rapidly, walking 
uphill, walking or stair c limbing after meals, in cold weather, in wind or when under 
emotional stress causes undue fatigue or dyspnea.  
III Symptoms with less than ordinary physical activity. Walking 1 to 2 blocks on the level 
and climbing more than one flight of stairs in normal conditions causes undue fatigue or 
dyspnea.  
IV Symptoms at rest. Inability to carry on any physical activity without fatigue or dyspnea.  
 
 